[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 379
1. Mele G, Pinna S, Melpignano A, Romano A, Brocca MC, Coppi MR, Quarta G: What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL? Leuk Res; 2007 Oct;31(10):1445-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of an elderly patient affected by Philadelphia positive Acute Lymphoblastic Leukaemia (Ph(+) ALL) who developed meningeal leukaemia during imatinib monotherapy, despite bone marrow molecular remission.
  • In view of the inefficacy of imatinib at preventing meningeal leukaemia for its poor penetration into the CNS, CNS prophylactic therapy should always be an integral part of any imatinib-based treatment strategy for Ph(+) ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Meningeal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use. Salvage Therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462730.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 04079A1RDZ / Cytarabine; 8A1O1M485B / Imatinib Mesylate; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Willems L, Suarez F, Messas E, Baubion N, Decaudin D, Fourquet A, Ghez D, Delarue R, Hermine O, Buzyn A, Varet B, Rubio MT: [High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer]. Bull Cancer; 2010 Feb;97(2):245-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer].
  • [Transliterated title] Risque élevé de dysfonction cardiaque des leucémies aiguës myéloïdes secondaires à un cancer du sein.
  • Secondary acute myeloid leukaemia (AML) occurring after breast cancer is a rare long-term complication of the chemo- and/or radiation therapy required to treat breast cancer.
  • The usually recognized curative option of these secondary AML includes courses of anthracycline-based chemotherapy followed by haematopoietic stem cell transplantation (HSCT).
  • As discussed here, an accurate evaluation of risk factors, the use of sensitive detection tests and of cardioprotective drugs as well as that of non-cardiotoxic chemotherapy might decrease the occurrence and severity of this life-threatening complication.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Breast Neoplasms. Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid / therapy. Neoplasms, Second Primary / therapy
  • [MeSH-minor] Acute Disease. Adult. Chemotherapy, Adjuvant / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Heart Diseases / chemically induced. Heart Diseases / drug therapy. Heart Diseases / physiopathology. Humans. Middle Aged. Remission Induction. Stroke Volume / drug effects. Stroke Volume / physiology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19819776.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; ZS7284E0ZP / Daunorubicin; FEC protocol
  •  go-up   go-down


3. Hardwick N, Chan L, Ingram W, Mufti G, Farzaneh F: Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer Immunol Immunother; 2010 Mar;59(3):379-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80.
  • Despite being of the myeloid lineage, acute myeloid leukaemia (AML) blasts are of low immunogenicity, probably because they lack the costimulatory molecule CD80 and secrete immunosuppressive factors.
  • Crucially, the response appears to be leukaemia specific, since stimulated patient PBMCs show higher frequencies of IFN-gamma secreting effector cells in response to AML blasts than to remission bone marrow cells from the same patients.
  • [MeSH-major] Antigens, CD80 / genetics. Interleukin-2 / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711075.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/D014301/1; United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/E005896/1; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Interleukin-2
  •  go-up   go-down


Advertisement
4. Sahin FI, Kizilkilic E, Bulakbasi T, Yilmaz Z, Boga C, Ozalp O, Karakus S, Ozdogu H: Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients. Clin Exp Med; 2007 Sep;7(3):102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients.
  • The role of cytogenetic findings in determining the diagnosis, therapy and prognosis of acute myeloid leukaemia (AML) has become more valuable by the day.
  • Chromosomal abnormalities were detected in 17 (25.7%) patients cytogenetically at the time of diagnosis, whereas molecular cytogenetic abnormalities were detected in 21 (31.8%) patients by fluorescence in situ hybridisation (FISH).
  • During clinical follow-up, 21 patients (31.8%) achieved complete remission (CR), 2 had partial remission (PR) (3.0%) and 4 patients had progressive disease (6.06%).
  • As for the normal karyotype, each patient displayed a different clinical course, which is probably due to the molecular changes in leukaemia-related genes.
  • Here we report our findings, which correlate with previous reports and conclude that cytogenetics is a crucial marker in leukaemia diagnosis and conventional and molecular cytogenetics should be performed as well as molecular genetic diagnostic methods.
  • [MeSH-major] Leukemia, Myeloid / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Cytogenetics. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):62-7 [15604893.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1855-8 [15178581.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Nov;56(2):235-45 [16207531.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2482-92 [11331327.001]
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):68-75 [15604894.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Nov;115(1):32-8 [10565297.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):352-8 [12733115.001]
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2526-31 [11895789.001]
  • (PMID = 17972052.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A, ALL-REZ BFM Study Group: Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer; 2008 Jan;44(2):257-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
  • PURPOSE: To investigate the cumulative incidence of and the risk factors for developing second malignant neoplasms (SMN) in children and adolescents following treatment for relapse of acute lymphocytic leukaemia (ALL).
  • METHODS: Patients (1376) up to 18 years of age with first relapse of non-B-cell ALL were treated and achieved a 2nd complete remission (CR).
  • RESULTS: Out of the 1376 patients 21 were diagnosed with SMN including non-lymphoblastic leukaemia/myelodysplastic syndrome (n=6), osteo-/Ewing's-/fibroblastic sarcoma (n=4), B-cell ALL/lymphoma (n=2), thyroid carcinoma (n=2), basal cell carcinoma, adeno carcinoma, squamous cell carcinoma, meningioma, malignant histiocytosis, glioblastoma and anaplastic astrocytoma (n=1 each).
  • SMN was found to be significantly associated with stem cell transplantation (SCT), and high cumulative doses of cranial irradiation, etoposide and cyclophosphamide.
  • CONCLUSIONS: Despite repeated exposure to intense frontline and relapse treatment (including multiagent chemotherapy, cranial irradiation and stem cell transplantation in some patients) the cumulative incidence of SMN was unexpectedly low, though significantly higher than in the general age-matched population.
  • [MeSH-major] Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Female. Germany / epidemiology. Humans. Incidence. Infant. Male. Multicenter Studies as Topic. Remission Induction. Risk Factors. Secondary Prevention

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981026.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Mertens R; Imbach P; Pongratz E; Rupprecht T; Henze G; Wickmann L; Otte J; Bode U; Eberl W; Pekrun A; Kirschstein M; Hofmann K; Frank R; Möbius D; Andler W; Niekrens C; Breu H; Suttorp M; Göbel U; Weinmann G; Sauerbrey A; Beck JF; Janka-Schaub G; Welte K; Kulozik A; Tautz C; Graf N; Fink FM; Zintl F; Hermann J; Rupprath G; Dupuis W; Rodehüser M; Schrappe M; Berthold F; Sternschulte W; Körholz D; Schmitt K; Selle B; Gutjahr P; Dürken M; Christiansen H; Rose M; Borkhardt A; Burdach S; Jürgens H; Scheurlen W; Eggers G; Geib R; Dickerhoff R; Bielack S; Rauh W; Niethammer D; Debatin KM; Gadner H; Dohrn B; Schlegel PG; Niggli F
  •  go-up   go-down


6. Maha A, Cheong SK, Leong CF, Seow HF: Cell viability of acute myeloid leukaemia blasts in culture correlates with treatment outcome. Hematology; 2008 Feb;13(1):13-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell viability of acute myeloid leukaemia blasts in culture correlates with treatment outcome.
  • Despite the advances in understanding the pathophysiology of acute myeloid leukaemia (AML), the cure rate for acute myeloid leukaemia patients remains low.
  • Acute myeloid leukaemia blasts demonstrated differing ability to survive in culture.
  • First, cells underwent maturation by increased expression of CD16 and down-regulated CD34 (a haemopoietic stem cell marker).
  • Thus, this study further supports the hypothesis that AML patients with poor survival may be related to having blasts with a biologically more immature or stem cell-like nature.
  • [MeSH-major] Cell Differentiation. Cell Proliferation. Granulocyte Precursor Cells / pathology. Leukemia, Myeloid, Acute / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis. Cell Survival. Child. Child, Preschool. Cohort Studies. Female. Humans. In Vitro Techniques. Infant. Male. Middle Aged. Phenotype. Remission Induction. Survival Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18534060.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Selleslag D: A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. Acta Biomed; 2006;77 Suppl 2:32-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a patient with acute lymphoblastic leukaemia successfully treated with AmBisome for a disseminated Fusarium solani infection that did not respond to first line treatment with voriconazole.
  • Despite the fact that he received additional myelosuppressive chemotherapy and underwent two stem cell transplantations from HLA mismatched donors the Fusarium infection did not recur during the subsequent phases of neutropenia.
  • The clinical presentation, diagnosis, prognosis and therapeutic options of fusariosis in immunocompromised patients are briefly discussed.
  • [MeSH-major] Abscess / drug therapy. Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Fusarium / isolation & purification. Muscular Diseases / drug therapy. Onychomycosis / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Combined Modality Therapy. Cytarabine / administration & dosage. Foot Dermatoses / drug therapy. Foot Dermatoses / microbiology. Humans. Imatinib Mesylate. Immunocompromised Host. Liposomes. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Pyrimidines / therapeutic use. Recurrence. Remission Induction. Reoperation. Rituximab. Teniposide / administration & dosage. Triazoles / therapeutic use. Voriconazole

  • MedlinePlus Health Information. consumer health - Abscess.
  • MedlinePlus Health Information. consumer health - Muscle Disorders.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918066.001).
  • [ISSN] 0392-4203
  • [Journal-full-title] Acta bio-medica : Atenei Parmensis
  • [ISO-abbreviation] Acta Biomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antifungal Agents; 0 / Benzamides; 0 / Liposomes; 0 / Piperazines; 0 / Pyrimidines; 0 / Triazoles; 0 / liposomal amphotericin B; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 7XU7A7DROE / Amphotericin B; 8A1O1M485B / Imatinib Mesylate; 957E6438QA / Teniposide; JFU09I87TR / Voriconazole
  •  go-up   go-down


8. Huang F, Parker W, Freeman CR: Feasibility and early outcomes of supine-position craniospinal irradiation. Pediatr Blood Cancer; 2010 Feb;54(2):322-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute toxicity included nausea/vomiting (N = 9), weight loss (median 10.3% (2.2-18.2), N = 10), lymphopenia (all), neutropenia (N = 3) and pancreatitis with Mallory-Weiss tear (N = 1).
  • After a median follow-up of 32.4 months (13.3-83.2), two patients recurred, two died of a second CNS malignancy, and one developed leukaemia.
  • All others remain in complete remission.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19890894.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Gallipoli P, Drummond MW: Pseudotumour cerebri as a manageable side effect of prolonged all-trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia. Eur J Haematol; 2009 Mar;82(3):242-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudotumour cerebri as a manageable side effect of prolonged all-trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Pseudotumor Cerebri / chemically induced. Pseudotumor Cerebri / therapy. Tretinoin / adverse effects. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Female. Humans. Remission Induction. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Haematol. 2009 May;82(5):411. Drummond, M W [added]
  • (PMID = 19018859.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


10. Dalal BI, Bruyere H, Barnett MJ: Significance of persistent Auer rods and cytogenetic abnormality after first cycle of therapy for acute promyelocytic leukaemia. Br J Haematol; 2007 Jun;137(5):385
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of persistent Auer rods and cytogenetic abnormality after first cycle of therapy for acute promyelocytic leukaemia.
  • [MeSH-major] Bone Marrow Examination. Chromosome Aberrations. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Humans. In Situ Hybridization, Fluorescence. Male. Oncogene Proteins, Fusion / genetics. Remission Induction. Translocation, Genetic. Tretinoin / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2008 Sep;142(6):998-1000 [18544082.001]
  • (PMID = 17374141.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


11. Kristensen IB, Møller H, Kjaerskov MW, Yderstraede K, Møller MB, Bergmann OJ: Myeloid sarcoma developing in pre-existing pyoderma gangrenosum. Acta Derm Venereol; 2009;89(2):175-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here a case of pyoderma gangrenosum in a patient with myelodysplastic syndrome developing into myeloid sarcoma as a sign of transformation to acute leukaemia.
  • The patient was treated successfully with intensive chemotherapy and achieved complete remission, and her otherwise expanding ulcers started to heal.
  • This is the first reported case of secondary blastic infiltration in pyoderma gangrenosum, and it underlines the importance of performing re-biopsy of non-healing ulcers, especially in patients with an underlying haematological disease.
  • [MeSH-minor] Cell Transformation, Neoplastic. Female. Humans. Leg Ulcer / etiology. Leg Ulcer / pathology. Leukemia, Myeloid, Acute / complications. Middle Aged


12. Turial S, Karabul N, Gutjahr P, Engel V, Bierschock S, Schier F: Ovarian tumours: late extramedullary recurrence of acute leukaemia. Eur J Pediatr Surg; 2009 Jun;19(3):184-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian tumours: late extramedullary recurrence of acute leukaemia.
  • OBJECTIVE: Isolated extramedullary relapse, especially ovarian recurrence, of acute leukaemia is rare.
  • MATERIALS AND METHODS: Over a 20-year period we observed two girls with ovarian relapse of acute lymphoblastic leukaemia (ALL) in over 300 treated children for ALL.
  • After having achieved complete haematological remission in the bone marrow, she stayed in remission for 18 months.
  • [MeSH-major] Bone Marrow Neoplasms / pathology. Neoplasm Recurrence, Local. Ovarian Neoplasms / secondary. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212934.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Lang K, Earle CC, Foster T, Dixon D, Van Gool R, Menzin J: Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging; 2005;22(11):943-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the treatment of acute myeloid leukaemia in the elderly.
  • INTRODUCTION: Acute myeloid leukaemia (AML) is the most common type of leukaemia among adults in the US.
  • These patients survived a median 18 months, with a median duration of remission of 8 months, and average total costs three times higher than the overall sample.
  • [MeSH-major] Drug Therapy / trends. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Cohort Studies. Female. Health Expenditures. Hospice Care / utilization. Humans. Male. Medicare. SEER Program. Survival Analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Nov;123(11):1203-10 [9366700.001]
  • [Cites] Med Care. 1999 May;37(5):445-56 [10335747.001]
  • [Cites] Eur J Haematol. 2002 Jun;68(6):376-81 [12225396.001]
  • [Cites] J Urol. 2001 Sep;166(3):861-5 [11490234.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):441-54 [14745859.001]
  • [Cites] Med Care. 1995 Aug;33(8):828-41 [7637404.001]
  • [Cites] Curr Oncol Rep. 2002 Sep;4(5):403-9 [12162914.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):307-16 [11773184.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Mar;6(1):46-59; discussion 86-7 [12060483.001]
  • [Cites] Med Care. 1999 May;37(5):436-44 [10335746.001]
  • [Cites] Med Care. 1999 Jul;37(7):706-11 [10424641.001]
  • [Cites] J Clin Epidemiol. 1999 May;52(5):463-70 [10360342.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1490-6 [11410481.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2311-8 [9116274.001]
  • [Cites] J Clin Epidemiol. 1996 Jan;49(1):95-103 [8598518.001]
  • [Cites] Health Care Financ Rev. 1997 Summer;18(4):51-76 [10175613.001]
  • [Cites] Br J Haematol. 1996 Jul;94(1):89-98 [8757514.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3880-9 [12920034.001]
  • [Cites] Health Care Financ Rev. 1996 Fall;18(1):237-46 [10165033.001]
  • [Cites] Drugs Aging. 2002;19(8):571-81 [12207551.001]
  • [Cites] Blood. 1991 Nov 15;78(10):2520-6 [1824249.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 2):2591-3 [9815662.001]
  • [Cites] Am J Manag Care. 2000 Oct;6(18 Suppl):S975-85 [11184568.001]
  • [Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]
  • [Cites] Leukemia. 1999 Oct;13(10):1481-90 [10516746.001]
  • [Cites] Blood. 1992 Apr 15;79(8):1924-30 [1562720.001]
  • [Cites] Med Care. 2000 Mar;38(3):281-9 [10718353.001]
  • [Cites] Cancer. 2003 Nov 15;98 (10 ):2095-104 [14601078.001]
  • [Cites] JAMA. 2000 Nov 15;284(19):2489-94 [11074779.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2760-6 [12767088.001]
  • [Cites] Clin Lymphoma. 2003 Aug;4 Suppl 1:S30-5 [14556673.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 3;84(11):872-7 [1593655.001]
  • [Cites] Blood. 2001 Sep 1;98 (5):1302-11 [11520775.001]
  • [Cites] Acta Oncol. 2001;40(2-3):231-52 [11441935.001]
  • [Cites] Ann Intern Med. 1997 Oct 15;127(8 Pt 2):666-74 [9382378.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1670-3 [10961861.001]
  • [Cites] Arch Intern Med. 2002 Jul 22;162(14):1597-603 [12123403.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-62-8 [12187170.001]
  • (PMID = 16323971.001).
  • [ISSN] 1170-229X
  • [Journal-full-title] Drugs & aging
  • [ISO-abbreviation] Drugs Aging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


14. Barbarroja N, Siendones E, Torres LA, Luque MJ, Martinez JM, Dorado G, Velasco F, Torres A, López-Pedrera C: MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia. Br J Haematol; 2008 Jul;142(1):27-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.
  • The hallmark of acute promyelocytic leukaemia (APL) is the reciprocal translocation t(15;17), which leads to the expression of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RARalpha) fusion protein and a cell differentiation blockade at the promyelocytic stage.
  • PML/RARalpha is directly targeted by all-trans-retinoic acid (ATRA), which degrades the oncoprotein and induces complete remission of malignancies.
  • The blockade of MEK/ERK pathway resulted in caspase-dependent degradation of PML/RARalpha, and attenuation of the cell differentiation induction.
  • [MeSH-major] Caspases / metabolism. Cell Transformation, Neoplastic / metabolism. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Leukemia, Promyelocytic, Acute / metabolism. Oncogene Proteins, Fusion / metabolism. Protein Kinase Inhibitors / pharmacology
  • [MeSH-minor] Adolescent. Adult. Apoptosis / drug effects. Cell Line, Tumor. Enzyme Activation / drug effects. Humans. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445086.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / Protein Kinase Inhibitors; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.22.- / Caspases
  •  go-up   go-down


15. Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Zeller B, Gustafsson G, Nordic Society of Pediatric Hematology and Oncology (NOPHO), AML Study Group: Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials. Leukemia; 2005 Dec;19(12):2090-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all, 447 children with acute myeloid leukaemia (AML) have been treated on three consecutive NOPHO studies from July 1984 to December 2001.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Protocols / standards. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Bone Marrow / drug effects. Child. Child, Preschool. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Remission Induction / methods. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304571.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


16. Yoshimi A, Niemeyer CM, Bohmer V, Duffner U, Strahm B, Kreyenberg H, Dilloo D, Zintl F, Claviez A, Wössmann W, Kremens B, Holter W, Niethammer D, Beck JF, Kontny U, Nöllke P, Klingebiel T, Bader P: Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. Br J Haematol; 2005 May;129(4):542-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia.
  • Chimaerism analysis was performed by polymerase chain reaction amplification of short-tandem repeat markers in 30 children following haematopoietic stem cell transplantation for juvenile myelomonocytic leukaemia (JMML).
  • Fourteen patients always had complete chimaerism (CC); one of them relapsed after the discontinuation of the study and 13 continued in complete remission (CR).
  • [MeSH-major] Leukemia, Myelomonocytic, Acute / surgery. Stem Cell Transplantation. Transplantation Chimera / genetics
  • [MeSH-minor] Child. Child, Preschool. Female. Follow-Up Studies. Genetic Markers. Graft vs Leukemia Effect. Humans. Infant. Leukocyte Transfusion. Male. Polymerase Chain Reaction / methods. Prospective Studies. Remission Induction. Survival Rate. Tandem Repeat Sequences

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15877738.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


17. Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group: Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol; 2009 Aug;146(3):292-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
  • Detection of minimal residual disease (MRD) after induction and consolidation therapy is highly predictive of outcome for childhood acute lymphoblastic leukaemia (ALL) and is used to identify patients at high risk of relapse in several current clinical trials.
  • To evaluate the prognostic significance of MRD at other treatment phases, MRD was measured by real-time quantitative polymerase chain reaction on a selected group of 108 patients enrolled on the Australian and New Zealand Children's Cancer Study Group Study VII including 36 patients with a bone marrow or central nervous system relapse and 72 matched patients in first remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500099.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


18. Stevens JM, Macdougall F, Jenner M, Oakervee H, Cavenagh J, Lister AT: Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre. Br J Haematol; 2009 Apr;145(1):40-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre.
  • This study assessed the recruitment to an acute myeloid leukaemia (AML) trial (AML15) in a single centre, evaluated whether outcome was influenced by trial entry and whether the trial population could be considered representative of all AML patients by retrospective comparison of patient characteristics, trial entry and outcome for 81 consecutive patients (<60 years).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials, Phase III as Topic. Leukemia, Myeloid, Acute / drug therapy. Patient Selection. Randomized Controlled Trials as Topic
  • [MeSH-minor] Adolescent. Adult. Age Factors. Female. Humans. Male. Middle Aged. Remission Induction. Selection Bias. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210510.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Apostolidou E, Swords R, Alvarado Y, Giles FJ: Treatment of acute lymphoblastic leukaemia : a new era. Drugs; 2007;67(15):2153-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute lymphoblastic leukaemia : a new era.
  • Acute lymphocytic leukaemia (ALL) is a heterogeneous group of disorders that result from the clonal proliferation and expansion of malignant lymphoid cells in the bone marrow, blood and other organs.
  • The optimal treatment of Philadelphia chromosome-positive patients requires the addition of BCR-ABL tyrosine kinase inhibitors, such as imatinib, whereas allogeneic stem-cell transplantation remains the preferred approach for high-risk patients in first remission.
  • Since only approximate, approximately 38% of adult ALL patients are free of disease 5 years after diagnosis and the outcome of salvage chemotherapy is very poor (complete remission rates of 20-30%, median survival of 3-6 months), novel agents are desperately required.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Animals. Chemistry, Pharmaceutical. Folic Acid Antagonists / therapeutic use. Humans. Microtubules / drug effects. Nucleosides / therapeutic use. Oncogene Proteins v-abl / antagonists & inhibitors. Proto-Oncogene Proteins c-bcr / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;46(5):427-32 [11127949.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):263-73 [10674898.001]
  • [Cites] Semin Oncol. 2005 Apr;32(2 Suppl 2):S5-8 [15818537.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1765-9 [16721371.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(6):521-31 [9118464.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1167-73 [12637486.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):832-8 [16467096.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1986 Summer;8(2):99-104 [3526939.001]
  • [Cites] Leuk Lymphoma. 1993;10 Suppl:147-50 [8481663.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2549-55 [17041099.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Blood. 2007 Apr 1;109 (7):2744-50 [17132721.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6615-24 [16166440.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):69-72 [10690390.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1464-8 [15054472.001]
  • [Cites] Curr Med Chem. 1999 Apr;6(4):329-52 [10101216.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):127-34 [9654112.001]
  • [Cites] Curr Opin Investig Drugs. 2005 Jun;6(6):623-30 [15988914.001]
  • [Cites] J Natl Cancer Inst. 1990 Oct 17;82(20):1641-2 [2145440.001]
  • [Cites] Clin Transl Oncol. 2006 Aug;8(8):560-5 [16952844.001]
  • [Cites] Anticancer Drugs. 1993 Feb;4(1):37-48 [8457713.001]
  • [Cites] Rev Pneumol Clin. 2005 Sep;61(4 Pt 2):4S5-7 [16273001.001]
  • [Cites] Pharmacol Ther. 1991 Oct;52(1):35-84 [1687171.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):401-12 [15923057.001]
  • [Cites] Int J Clin Pharmacol Ther. 2005 Dec;43(12):567-9 [16372519.001]
  • [Cites] Circ Res. 1999 Aug 6;85(3):221-8 [10436164.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10 (16):5335-41 [15328169.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1639-45 [16087696.001]
  • [Cites] Cancer Res. 1977 Feb;37(2):535-40 [264412.001]
  • [Cites] J Med Chem. 2002 Oct 24;45(22):4913-22 [12383017.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4937-43 [10519407.001]
  • [Cites] Biochem Pharmacol. 2003 Apr 1;65(7):1163-70 [12663051.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5929-37 [16135464.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5601-7 [6352020.001]
  • [Cites] Mol Pharmacol. 1995 Sep;48(3):459-71 [7565626.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] Blood. 2007 May 15;109 (10 ):4164-7 [17264295.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):253-65 [15057285.001]
  • [Cites] N Engl J Med. 1986 Sep 11;315(11):657-63 [2943992.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33(5):359-65 [8306408.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Sep 26;55(10 ):1293-302 [14499708.001]
  • [Cites] Cell Prolif. 1992 Nov;25(6):523-36 [1457603.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Carbohydr Res. 1985 Feb 28;136:391-6 [4005892.001]
  • [Cites] Invest New Drugs. 1999;17(1):81-7 [10555126.001]
  • [Cites] Lancet. 1987 Apr 4;1(8536):786-9 [2882192.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(6):461-70 [9788572.001]
  • [Cites] Leukemia. 1998 May;12(5):660-5 [9593262.001]
  • [Cites] Biochem Pharmacol. 2001 Apr 1;61(7):857-65 [11274972.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2039-44 [9447817.001]
  • [Cites] Lancet Oncol. 2005 Aug;6(8):548 [16094758.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Nov;4(11):804-5 [17143248.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):649-55 [11531245.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1583-9 [8453627.001]
  • [Cites] Ann Pharmacother. 1997 May;31(5):616-24 [9161659.001]
  • [Cites] Invest New Drugs. 1986;4(1):85-105 [3516918.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54(3):273-81 [15173957.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5136-42 [17344466.001]
  • [Cites] J Med Chem. 1994 Jul 8;37(14):2167-74 [8035423.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Jul 9;11(13):1671-3 [11425534.001]
  • [Cites] Blood. 1997 Feb 1;89(3):1013-8 [9028333.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1328-33 [16614241.001]
  • [Cites] J Med Chem. 1993 Mar 19;36(6):758-64 [8459402.001]
  • [Cites] Anticancer Drugs. 2002 Sep;13(8):797-805 [12394263.001]
  • [Cites] Eur J Haematol. 2006 Oct;77(4):293-9 [16856922.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):767-74 [15146568.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(4):351-5 [8548881.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7161-7 [16192600.001]
  • [Cites] Nat Genet. 2004 May;36(5):453-61 [15098032.001]
  • [Cites] EMBO J. 2002 Nov 1;21(21):5766-74 [12411494.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(12):1137-43 [9894715.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):199-203 [9428769.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):896-904 [7547237.001]
  • [Cites] J Med Chem. 2001 Dec 6;44(25):4416-30 [11728187.001]
  • [Cites] Mol Pharmacol. 1995 Oct;48(4):758-65 [7476904.001]
  • [Cites] Clin Lung Cancer. 2004 Apr;5 Suppl 2:S75-9 [15117429.001]
  • [Cites] Adv Exp Med Biol. 1984;165 Pt B:309-14 [6609537.001]
  • [Cites] Cancer. 1976 Jan;37(1):220-8 [1061636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11598-602 [8265596.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2155-60 [8374873.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2A):1277-83 [10368688.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1203-9 [10506705.001]
  • [Cites] Annu Rev Med. 1997;48:353-74 [9046968.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] J Med Chem. 1998 Dec 17;41(26):5310-9 [9857098.001]
  • [Cites] Cancer Chemother Pharmacol. 2001;47(2):179-84 [11269745.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):120-7 [16331634.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Apr;57(4):427-35 [16322992.001]
  • [Cites] Int J Exp Pathol. 2002 Feb;83(1):21-38 [12059907.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72 (5):844-50 [9311603.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):697-705 [10080616.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):727-37 [9615712.001]
  • [Cites] Adv Exp Med Biol. 1993;338:461-4 [8304158.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3658-61 [11369666.001]
  • [Cites] Cancer. 1994 May 15;73(10):2515-9 [8174048.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1702-6 [8137285.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1479-84 [8137251.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2449-56 [16258975.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:148-52 [1578919.001]
  • [Cites] Biochemistry. 1997 Apr 15;36(15):4399-411 [9109647.001]
  • [Cites] J Med Chem. 1991 Feb;34(2):574-9 [1995880.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26 [15087948.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):17-8 [16485343.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5329-35 [17000665.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):982-92 [15709163.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Sep;298(3):1206-12 [11504822.001]
  • [Cites] Biochem Pharmacol. 1996 May 17;51(10):1331-40 [8787549.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):14-20 [11148680.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1780-6 [8355045.001]
  • [Cites] Mol Cancer Ther. 2002 Feb;1(4):275-86 [12467223.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Eur J Cancer. 1991;27(4):482-7 [1827725.001]
  • [Cites] Expert Opin Investig Drugs. 2003 May;12(5):853-63 [12720495.001]
  • [Cites] Jpn J Cancer Res. 1998 Sep;89(9):954-62 [9818032.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;Suppl:S16-7 [15962527.001]
  • [Cites] Pediatr Nurs. 1995 Sep-Oct;21(5):471-4, 490 [8684851.001]
  • [Cites] Biochemistry. 1964 Jan;3:15-8 [14114497.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jul;50(1):6-8 [12111105.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Biochem Biophys Res Commun. 1972 May 26;47(4):685-91 [5026289.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3036-50 [9679969.001]
  • [Cites] Cancer Res. 1976 Apr;36(4):1499-502 [1260766.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1986-94 [11877270.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4341-4 [11389057.001]
  • [Cites] Hematol J. 2002;3(1):2-6 [11960387.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1843-9 [9816139.001]
  • [Cites] Clin Colorectal Cancer. 2005 Nov;5(4):257-62 [16356302.001]
  • [Cites] Leuk Lymphoma. 1993;10 Suppl:153-7 [8481665.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3288-94 [16368880.001]
  • [Cites] J Clin Oncol. 1988 Apr;6(4):583-7 [3282032.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4260-6 [2194651.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1421-3 [16601247.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 15;55(8):1229-34 [9719477.001]
  • (PMID = 17927282.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Folic Acid Antagonists; 0 / Nucleosides; 0 / Oncogene Proteins v-abl; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  • [Number-of-references] 159
  •  go-up   go-down


20. Jourdan E, Rigal-Huguet F, Marit G, Vey N, Dastugue N, Fegueux N, Molina L, Gastaut JA, Legros L, Zerazhi H, Cailleres S, Bauduer F, Bordessoule D, Attal M, Blaise D, Pigneux A, BGMT Study Group: One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. Br J Haematol; 2005 May;129(3):403-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
  • We report on a randomized trial aimed to determine the impact of a second consolidative high-dose cytarabine-based chemotherapy (HiDAC) in patients with acute myeloid leukaemia prior to an autologous stem cell transplantation (ASCT).
  • Patients aged 18-60 years, in complete remission (CR) received a first consolidation with daunorubicin and cytarabine at reduced dose.
  • Overall survival, leukaemia-free survival and cumulative incidence of relapse and non-relapse deaths were 41% and 53% (P = 0.14), 39% and 48% (P = 0.12), 57% and 47% (P = 0.11), 8% and 8% (P = 0.95) for HiDAC 1 and HiDAC 2 groups, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Daunorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Multivariate Analysis. Recurrence. Remission Induction. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842665.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


21. Vehreschild JJ, Böhme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G, Drzisga I, Cornely OA: A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect; 2007 Nov;55(5):445-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
  • We conducted a trial to analyze the efficacy and safety of voriconazole in the prevention of lung infiltrates during induction chemotherapy for acute myelogenous leukaemia (AML).
  • METHODS: This was a prospective, randomised, double-blind, placebo-controlled phase III trial in AML patients undergoing remission induction chemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / prevention & control. Mycoses / prevention & control. Pyrimidines / adverse effects. Pyrimidines / therapeutic use. Triazoles / adverse effects. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822770.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Placebos; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  •  go-up   go-down


22. Ferrara F, Palmieri S, Izzo T, Criscuolo C, Riccardi C: Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome. Hematol Oncol; 2010 Dec;28(4):202-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
  • Acute myeloid leukaemia (AML) secondary to myelodysplastic syndrome (MDS) is characterized by poor prognosis, namely in older patients.
  • In patients achieving CR, an additional course, followed by G-CSF to mobilize CD34+ cells and subsequent autologous stem cell transplantation (ASCT) were programmed.
  • Overall, 43 patients (67%) achieved complete remission (CR).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Myelodysplastic Syndromes / complications
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Diarrhea / chemically induced. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Remission Induction. Transplantation, Autologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives


23. Brethon B, Yakouben K, Oudot C, Boutard P, Bruno B, Jérome C, Nelken B, de Lumley L, Bertrand Y, Dalle JH, Chevret S, Leblanc T, Baruchel A: Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol; 2008 Nov;143(4):541-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia.
  • Gemtuzumab ozogamicin (GO) monotherapy is reported to yield a 20-30% response rate in advanced acute myeloid leukaemia (AML).
  • At the outset of GOCYT, two patients were refractory; eight patients were in refractory first relapse; six patients had relapsed after stem cell transplantation (SCT); and one patient [del(5q) therapy-related AML (t-AML)] had not yet been treated.
  • Ten responses were obtained after GOCYT induction, including complete remission (CR) or CR without complete recovery of platelets (CRp) in six patients (35%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Aug;146(3):342-4 [19545292.001]
  • (PMID = 18759760.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab; 04079A1RDZ / Cytarabine
  •  go-up   go-down


24. Brkljacic B, Cikara I, Ivanac G, Hrkac Pustahija A, Zic R, Stanec Z: Ultrasound-guided bipolar radiofrequency ablation of breast cancer in inoperable patients: a pilot study. Ultraschall Med; 2010 Apr;31(2):156-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were at high-risk for general anesthesia and surgery because of severely impaired cardiac function, advanced age, or associated diseases (acute myeloid leukaemia (AML), diabetes, hypertension, depression) and/or refused surgery.
  • The Patient with AML and BCA had an infection of the treated breast after 4 months and postponed mastectomy to an AML remission status.
  • There were no signs of malignancy in histopathology; the patient finally died of leukemia 42 months after RFA.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 19941254.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Breems DA, Löwenberg B: Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. Br J Haematol; 2005 Sep;130(6):825-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.
  • Most adult patients under 60 years with acute myeloid leukaemia (AML) who achieve a complete remission after induction chemotherapy will relapse if they do not receive further therapy.
  • Consolidation treatment with autologous stem cell transplantation (SCT) is one option that has been studied extensively.
  • High-dose cytotoxic therapy followed by autologous SCT or intensive cycles of chemotherapy furnish overall approximately similar probabilities of survival when applied in first remission.
  • Particular issues discussed are the value of autologous SCT in different prognostic subsets of AML and the value of autologous mobilised peripheral blood stem cell transplants, which offer a much faster haematopoietic recovery.
  • [MeSH-major] Leukemia, Myeloid / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Acute Disease. Adult. Hematopoietic Stem Cell Mobilization. Humans. Peripheral Blood Stem Cell Transplantation / methods. Prognosis

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16156852.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 66
  •  go-up   go-down


26. Ommen HB, Nyvold CG, Braendstrup K, Andersen BL, Ommen IB, Hasle H, Hokland P, Ostergaard M: Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol; 2008 Jun;141(6):782-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.
  • We hypothesized that Wilms tumour 1 gene (WT1) expression levels in acute myeloid leukaemia (AML) patients might have predictive value and reveal molecular relapse kinetics.
  • WT1 level was determined at diagnosis, during therapy and post-therapy follow-up in 89 patients who reached first complete remission (CR1) (952 samples, median 8 samples/patient, range 2-38).
  • By grouping 34 BM and 99 peripheral blood (PB) complete remission samples in monthly intervals prior to clinical relapse, disease development was delineated and a simple mathematical model constructed, that allowed for the prediction of relapse detection rates (RDRs) as well as median times [t(m)s] from WT1 positivity to clinical relapse.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Leukemia, Myeloid, Acute / metabolism. Models, Biological. WT1 Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Examination / methods. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410450.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / WT1 Proteins
  •  go-up   go-down


27. Orsi C, Bartolozzi B, Messori A, Bosi A: Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation. Bone Marrow Transplant; 2007 Oct;40(7):643-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation.
  • Allogeneic transplantation in patients with acute lymphoblastic leukaemia in first remission (ALL-CR1) has been studied in several clinical trials.
  • [MeSH-major] Bone Marrow Transplantation / physiology. Disease-Free Survival. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660839.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Di Febo A, Laurenti L, Falcucci P, Tosti ME, Fianchi L, Pagano L, Leone G: All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients. Am J Ther; 2007 Jul-Aug;14(4):351-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients.
  • All-trans retinoic acid (ATRA) has shown a synergistic activity in combination with cytosine arabinoside in vitro in the treatment of acute myeloid leukaemia (AML).
  • In this paper we report the results of treatment with low dose cytosine arabinoside (LDAC) with or without ATRA in 28 patients with acute myeloid leukaemia aged over 60 years: 14 patients received only LDAC and the other 14 LDAC + ATRA.
  • All the patients received subcutaneous (sc) LDAC (15 mg twice a day for 14 days) and in 14 patients oral ATRA (45 mg/sqm in the same days) was added to LDAC; the courses were repeated every 4 weeks from diagnosis to relapse.
  • No statistically significant differences were observed in complete remission rate (21% vs. 50%, respectively) and resistant rate (57% vs. 29%), but the patients treated with the combination of the 2 drugs had a better time to treatment failure (15 weeks vs. 30 weeks, respectively) (P = 0.045) and a longer survival (37 weeks vs. 66 weeks) (P = 0.019).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Cytarabine / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Remission Induction. Tretinoin / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667210.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin
  •  go-up   go-down


29. Adam Z, Pour L, Krejcí M, Korístek Z, Navrátil M, Krivanová A, Zahradová L, Hájek R: [Treatment of Waldenström macroglobulinaemia--the experience of one centre]. Vnitr Lek; 2009 Jan;55(1):9-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age upon diagnosis of the symptomatic form of WM and start of treatment was 59 (51-78) years.
  • Decrease in immunoglobulin concentration under the lower physiological limit is not referred to as a characteristic sign of WM, yet it was recorded in 7 out of 19 patients in our patient group and continued after chemotherapy, with the affected patients suffering from infections in remission more often than those with physiological values of immunoglobulins.
  • The first line of treatment achieved complete remission (CR) in 15% cases (3/15).
  • Partial remission (PR) was achieved by 63% of patients (12/19).
  • The first relaps of the disease was recorded in 5 patients (2 of whom had PR and 3 MR) who achieved remission after additional lines of therapy.
  • Thirteen patients are in the first PR.
  • Additional malignant disease was diagnosed in 3 patients: 1 colon carcinoma, 1 acute myeloid leukaemia (AML) and 1 myelodysplastic syndrome (MDS).
  • Of the three patients only the patient with MDS has survived and is now without any evidence of the presence of WM, i.e. in complete remission at 41 months after the start of therapy.
  • It is not possible to determine the median of the first remission or the median of total survival due to the short follow up interval.
  • [MeSH-major] Waldenstrom Macroglobulinemia / diagnosis. Waldenstrom Macroglobulinemia / drug therapy


30. Schuster F, Moelter C, Schmid I, Graubner UB, Kammer B, Belohradsky BH, Führer M: Successful antifungal combination therapy with voriconazole and caspofungin. Pediatr Blood Cancer; 2005 Jun 15;44(7):682-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 12-year-old boy in third remission of an acute lymphoblastic leukaemia developed infection of lung and paranasal sinuses with Aspergillus flavus in neutropenia.
  • Because of the high risk of leukaemia-relapse bone marrow transplantation (BMT) from a matched unrelated donor was carried out despite invasive pulmonary aspergillosis (IPA).
  • [MeSH-major] Antifungal Agents / therapeutic use. Aspergillosis / drug therapy. Aspergillus / drug effects. Lung Diseases, Fungal / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15700260.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Peptides, Cyclic; 0 / Pyrimidines; 0 / Triazoles; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  •  go-up   go-down


31. Cleaver AL, Beesley AH, Firth MJ, Sturges NC, O'Leary RA, Hunger SP, Baker DL, Kees UR: Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study. Mol Cancer; 2010 May 12;9:105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study.
  • BACKGROUND: Continuous complete clinical remission in T-cell acute lymphoblastic leukemia (T-ALL) is now approaching 80% due to the implementation of aggressive chemotherapy protocols but patients that relapse continue to have a poor prognosis.
  • Such patients could benefit from augmented therapy if their clinical outcome could be more accurately predicted at the time of diagnosis.
  • In T-ALL cell lines, low IL-7R expression was correlated with diminished growth response to IL-7 and enhanced glucocorticoid resistance.
  • Analysis of biological pathways identified the NF-kappaB and Wnt pathways, and the cell adhesion receptor family (particularly integrins) as being predictive of relapse.
  • CONCLUSIONS: We have used two different approaches to identify, for the first time, robust gene signatures that can successfully discriminate relapse and CCR patients at the time of diagnosis across multiple patient cohorts and platforms.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2006 Jul;20(7):1197-205 [16688226.001]
  • [Cites] Oncogene. 2006 May 25;25(22):3113-22 [16407823.001]
  • [Cites] PLoS Med. 2006 Mar;3(3):e47 [16417408.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1537-44 [17117183.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5742-9 [17179108.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] J Immunol. 2007 Apr 15;178(8):5132-43 [17404296.001]
  • [Cites] Br J Haematol. 2007 May;137(4):319-28 [17456054.001]
  • [Cites] Prostate. 2007 Jun 15;67(9):955-67 [17440963.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1198-203 [17410184.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1429-38 [17495134.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2324-30 [17609427.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2548-55 [18039957.001]
  • [Cites] Br J Haematol. 2008 Mar;140(6):656-64 [18302714.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Blood. 2008 May 1;111(9):4477-89 [18285545.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7924-9 [19047123.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2142-50 [18818707.001]
  • [Cites] Leukemia. 2009 Jan;23(1):43-52 [18987663.001]
  • [Cites] Lancet Oncol. 2009 Feb;10(2):147-56 [19147408.001]
  • [Cites] Br J Cancer. 2009 Jun 16;100(12):1926-36 [19436302.001]
  • [Cites] Nature. 2009 Jun 18;459(7249):1000-4 [19536265.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1053-62 [19406988.001]
  • [Cites] Leukemia. 1999 Nov;13(11):1696-707 [10557041.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Cell Sci. 2000 Jul;113 ( Pt 13):2385-97 [10852818.001]
  • [Cites] Blood. 2000 Jul 1;96(1):297-306 [10891465.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31285-95 [11371555.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4109-15 [12010814.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Blood. 2002 Aug 1;100(3):991-7 [12130513.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Leukemia. 2003 May;17(5):887-93 [12750702.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Cancer Sci. 2004 May;95(5):385-92 [15132764.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1333-8 [7478554.001]
  • [Cites] BMC Bioinformatics. 2005;6:97 [15826317.001]
  • [Cites] BMC Genomics. 2005;6:59 [15854232.001]
  • [Cites] Leuk Lymphoma. 2005 Apr;46(4):483-95 [16019476.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):513-33 [15996891.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7851-60 [16278408.001]
  • [Cites] Br J Haematol. 2005 Nov;131(4):447-56 [16281934.001]
  • [Cites] BMC Cancer. 2006;6:229 [17002788.001]
  • (PMID = 20459861.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / CA95475; United States / NCI NIH HHS / CA / CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NF-kappa B; 0 / Receptors, Interleukin-7; 0 / Wnt Proteins
  • [Other-IDs] NLM/ PMC2879253
  •  go-up   go-down


32. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, Allen C, Green C, Quentmeier H, Drexler H, Burnett A, Linch D, Bonnet D, Lister TA, Fitzgibbon J: Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol; 2008 Nov 20;26(33):5429-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.
  • PURPOSE: To determine the clinical relevance of Wilms' tumor 1 (WT1) gene mutations in acute myeloid leukemia (AML) with normal karyotype (NK).
  • Patients with WT1 mutations had an inferior response to induction chemotherapy compared with wild-type cases (complete remission rate, 79% v 90%, odds ratio [OR] = 3.02; 95% CI, 1.17 to 7.82; P = .02), a higher rate of resistant disease (15% v 4%; OR = 9.33; 95% CI, 2.38 to 36.6; P = .001), an increased cumulative incidence of relapse (67% v 43%, hazard ratio [HR] = 3.02; 95% CI, 1.69 to 5.38; P = .0008), with a reduction in both relapse-free survival (22% v 44%; HR = 2.16; 95% CI, 1.32 to 3.55; P = .005) and overall survival (26% v 47%; HR = 1.91; 95% CI, 1.23 to 2.95; P = .007) at 5 years.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Genes, Wilms Tumor. Leukemia, Myeloid, Acute / genetics. Mutation


33. Betts DR, Ammann RA, Hirt A, Hengartner H, Beck-Popovic M, Kuhne T, Nobile L, Caflisch U, Wacker P, Niggli FK: The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). Eur J Haematol; 2007 Jun;78(6):468-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG).
  • In childhood-onset acute myeloid leukaemia (AML) the clinical value of karyotypic aberrations is now acknowledged, although there is still debate concerning the prognostic significance of some events.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Female. Humans. In Situ Hybridization, Fluorescence. Incidence. Karyotyping. Male. Prognosis. Remission Induction. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419750.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


34. Pession A, Rondelli R, Basso G, Rizzari C, Testi AM, Fagioli F, De Stefano P, Locatelli F, AML Strategy & Study Committee of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP): Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia; 2005 Dec;19(12):2043-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols.
  • Since 1982, four consecutive studies on childhood acute myeloid leukaemia (AML) (namely LAM-82, -87, -87M and -92) have been conducted in Italy by the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) group.
  • Patients with acute promyelocytic leukaemia (20% of diagnoses) were included in LAM-87 and 87M studies.
  • Postremissional therapy significantly changed over time, with an ever-increasing role given to stem cell transplantation (SCT).
  • [MeSH-major] Antineoplastic Protocols / standards. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Infant. Infant, Newborn. Male. Remission Induction / methods. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16107897.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


35. Baba S, Matsuo T, Ishizaka S, Morikawa M, Suyama K, Nagata I: [Intracranial granulocytic sarcoma extending from the posterior fossa to the carotid space via the jugular foramen: a case report]. No Shinkei Geka; 2010 Jan;38(1):53-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a focal lesion seen in 2-10.9% of acute myelogenous leukaemia (AML) patients.
  • It usually develops either concurrently with the AML or after a remission.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20085103.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Yilmaz M, Dagdas S, Aki SZ, Guler N, Akoz AG, Erdin Z, Alanoglu G, Ozet G: The relation between plasminogen activator inhibitor activity and disease activation in acute myeloblastic leukaemia patients. Clin Lab Haematol; 2006 Oct;28(5):313-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relation between plasminogen activator inhibitor activity and disease activation in acute myeloblastic leukaemia patients.
  • Coagulation and fibrinolytic abnormalities are common in patients with acute myeloblastic leukaemia (AML) like other forms of leukaemias.
  • In this study, we investigated if total plasminogen activator inhibitor (PAI) activity, which is believed to increase in initial diagnosis and relapse in AML patients could be accepted as a relapse criterion or not.
  • The patients' diagnosis were based on clinical criteria as well as morphological, cytochemical, immunuphenotypic examinations of peripheral blood and bone marrow specimens.
  • We found significant difference in total PAI activity between patients who have active disease and remission.
  • In conclusion, the total PAI activity could be accepted as a relapse and an initial diagnosis criterion of AML patients during follow up.
  • [MeSH-major] Leukemia, Myeloid, Acute / blood. Plasminogen Activator Inhibitor 1 / blood. Plasminogen Activator Inhibitor 2 / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999721.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Plasminogen Activator Inhibitor 1; 0 / Plasminogen Activator Inhibitor 2
  •  go-up   go-down


37. Reinfjell T, Lofstad GE, Nordahl HM, Vikan A, Diseth TH: Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning. Eur J Cancer Care (Engl); 2009 Jul;18(4):364-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning.
  • Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioningThe objective of this study is to assess the mental health and psychosocial adjustment of children in remission from acute lymphoblastic leukaemia (ALL), and parental functioning compared to healthy controls.
  • Children in remission from ALL showed on average significantly more problems regarding mental health and psychosocial adjustment, as reported by their parents, compared with healthy controls.
  • Adequate rehabilitation and follow-up programmes should be implemented for children in remission from ALL.
  • [MeSH-major] Adaptation, Psychological. Mental Disorders / epidemiology. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology
  • [MeSH-minor] Adolescent. Adult. Anxiety / epidemiology. Child. Cross-Sectional Studies. Depression / epidemiology. Female. Health Status. Humans. Male. Middle Aged. Norway. Remission Induction. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473372.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Duval A, Rivet J, Moulonguet I, Cassar O, Agbalika F, Wallach D, Gessain A, Petit A: Atypical presentation of adult T-cell leukaemia/lymphoma due to HTLV-1: prurigo nodularis lasting twelve years followed by an acute micropapular eruption. Acta Derm Venereol; 2010 May;90(3):287-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical presentation of adult T-cell leukaemia/lymphoma due to HTLV-1: prurigo nodularis lasting twelve years followed by an acute micropapular eruption.
  • Human T-cell lymphotropic virus type 1 (HTLV-1) causes adult T-cell leukaemia/lymphoma.
  • A 52-year-old black man, from the French West Indies, who had had prurigo nodularis for 12 years, presented with a distinct micropapular eruption with the typical pathological picture of epidermotropic T-cell lymphoma.
  • Based on HTLV-1-positive serology and monoclonal integration of HTLV-1 we diagnosed smouldering adult T-cell leukaemia/lymphoma.
  • Treatment with alpha-interferon, 3 x 106 units three times a week, associated with zidovudine, 1 g daily, resulted in complete remission within 4 months.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / virology. Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Prurigo / virology. Skin / virology

  • Genetic Alliance. consumer health - Prurigo nodularis.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526548.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / IL2RA protein, human; 0 / Interferon-alpha; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Recombinant Proteins; 4B9XT59T7S / Zidovudine; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


39. Bhatti FA, Hussain I, Ali MZ: Adult B lymphoblastic leukaemia/lymphoma with hypodiploidy (-9) and a novel chromosomal translocation t(7;12)(q22;p13) presenting with severe eosinophilia - case report and review of literature. J Hematol Oncol; 2009;2:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult B lymphoblastic leukaemia/lymphoma with hypodiploidy (-9) and a novel chromosomal translocation t(7;12)(q22;p13) presenting with severe eosinophilia - case report and review of literature.
  • Patients suffering from adult acute lymphoblastic leukemia are acutely ill and present most commonly with fever, pallor, bleeding, lymphadenopathy, hepatosplenomegaly and presence of lymphoblasts in the peripheral blood and bone marrow.
  • We describe a rare presentation of acute lymphoblastic leukemia, in a young adult male who had vague and minimal symptoms with mild splenomegaly.
  • The blasts were positive for common precursor B cell markers on flow cytometry.
  • The patient had a unique cytogenetic abnormality t(7;12)(q22;p13),-9, not previously described in acute lymphoblastic leukemia.
  • He was categorized as poor risk due to failure to achieve complete remission after induction with UK ALL XII chemotherapy.
  • [MeSH-major] Eosinophilia / complications. Eosinophilia / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Dev Pathol. 2003 Nov-Dec;6(6):558-63 [15018456.001]
  • [Cites] Blood. 1973 Sep;42(3):377-84 [4516523.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):382-90 [3546615.001]
  • [Cites] Br J Haematol. 1987 Sep;67(1):25-31 [3478077.001]
  • [Cites] Acta Haematol. 1989;82(2):85-90 [2508400.001]
  • [Cites] Blood. 1990 Jul 15;76(2):285-9 [2114933.001]
  • [Cites] Pediatr Hematol Oncol. 1992 Apr-Jun;9(2):151-5 [1388044.001]
  • [Cites] Blood. 1996 May 1;87(9):3579-86 [8611680.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2459-63 [8630411.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):287-95 [9031109.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2036-41 [9058725.001]
  • [Cites] N Engl J Med. 1998 May 28;338(22):1592-600 [9603798.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3038-45 [15284118.001]
  • [Cites] Lab Hematol. 2008;14(1):7-9 [18403314.001]
  • [Cites] Chin Med J (Engl). 2008 Sep 5;121(17):1744-6 [19024110.001]
  • [Cites] Oncogene. 2000 Feb 17;19(7):906-15 [10702799.001]
  • [Cites] Ann Hematol. 2000 May;79(5):272-4 [10870483.001]
  • [Cites] Blood. 2001 Feb 15;97(4):1050-5 [11159536.001]
  • [Cites] Leukemia. 2001 Jun;15(6):915-20 [11417477.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):191-200 [12939747.001]
  • [Cites] Br J Haematol. 2003 Dec;123(5):955-6 [14632791.001]
  • [Cites] Pediatr Dermatol. 2003 Nov-Dec;20(6):502-5 [14651570.001]
  • (PMID = 19545391.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 26
  • [Other-IDs] NLM/ PMC2706857
  •  go-up   go-down


40. Swords R, Nolan A, Fay M, Quinn J, O'Donnell R, Murphy PT: Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab. Clin Lab Haematol; 2006 Feb;28(1):57-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with cold-type autoimmune haemolytic anaemia for 8 years developed progressive B cell chronic lymphocytic leukaemia (CLL).
  • This resulted in a marked acute increase in haemolysis shortly after completing each course of fludarabine.
  • FCR resulted in complete clinical remission of CLL but residual haemolysis persisted.
  • The patient was then given four weekly infusions of single agent rituximab, resulting in ongoing remission of haemolysis.
  • In addition, subsequent single agent rituximab therapy resulted in prolonged remission of cold-type autoimmune haemolytic anaemia.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / complications. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / adverse effects. Hemolysis / drug effects. Immunologic Factors / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430461.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


41. Wheatley K, Goldstone AH, Littlewood T, Hunter A, Burnett AK: Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol; 2009 Jun;146(1):54-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party.
  • The role of granulocyte colony stimulating factor (G-CSF) as supportive therapy following intensive induction chemotherapy for acute myeloid leukaemia (AML) in adults was investigated in a randomized trial.
  • Complete remission (CR) rates were similar between arms (73% G-CSF, 75% placebo, P = 0.5), as were reasons for failure (induction death: P = 0.7; resistant disease: P = 0.5) and, for remitters, 5-year disease-free survival (34% vs. 38%, P = 0.3).
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chi-Square Distribution. Disease-Free Survival. Female. Humans. Length of Stay. Male. Middle Aged. Proportional Hazards Models. Prospective Studies. Recombinant Proteins / therapeutic use. Remission Induction / methods. Survival Rate. Treatment Outcome. United Kingdom. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438472.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300133
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6WS4C399GB / lenograstim
  •  go-up   go-down


42. Selwood K, Pizer B, Gibson B, Skinner R, United Kingdom Children's Cancer Study Group (UKCCSG)/Paediatric Oncology Nursing Forum (PONF) Supportive Care Group, and the Medical Research Council (MRC) Childhood Leukaemia Working Party (CLWP): Vascular access for daunorubicin during childhood acute lymphoblastic leukaemia induction treatment: a UKCCSG supportive care group and MRC childhood leukaemia working party survey. Eur J Oncol Nurs; 2008 Dec;12(5):476-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular access for daunorubicin during childhood acute lymphoblastic leukaemia induction treatment: a UKCCSG supportive care group and MRC childhood leukaemia working party survey.
  • Daunorubicin was reintroduced into induction chemotherapy in UK protocols for intermediate- and high-risk childhood acute lymphoblastic leukaemia in 1999.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Catheterization, Central Venous / statistics & numerical data. Catheterization, Peripheral / statistics & numerical data. Daunorubicin / administration & dosage. Practice Patterns, Physicians' / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Child. Extravasation of Diagnostic and Therapeutic Materials / etiology. Extravasation of Diagnostic and Therapeutic Materials / prevention & control. Great Britain. Guideline Adherence. Health Care Surveys. Humans. Infusions, Intravenous / adverse effects. Infusions, Intravenous / methods. Patient Selection. Practice Guidelines as Topic. Remission Induction / methods. Surveys and Questionnaires. Thromboembolism / etiology. Thromboembolism / prevention & control. Time Factors

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926774.001).
  • [ISSN] 1462-3889
  • [Journal-full-title] European journal of oncology nursing : the official journal of European Oncology Nursing Society
  • [ISO-abbreviation] Eur J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


43. Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M: Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Br J Haematol; 2005 Oct;131(2):172-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
  • Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated induction regimen for the treatment of acute myeloid leukaemia (AML).
  • Fifty-seven patients received FLAI, as the first induction-remission course, and 55 patients received ICE.
  • After HDAC, patients in complete remission (CR) received a second consolidation course (mitoxantrone, etoposide, Ara-C) and autologous stem cell transplantation (auto-SCT) or allogeneic (allo)-SCT, according to the age, disease risk and donor availability.
  • Both haematological (P = 0.002) and non-haematological (P = 0.0001) toxicities, especially gastrointestinal (i.e. nausea, vomiting, mucositis and diarrhoea), were significantly lower in FLAI arm.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Idarubicin / administration & dosage. Karyotyping. Leukocyte Count. Male. Middle Aged. Prospective Studies. Remission Induction. Stem Cell Transplantation. Transplantation Conditioning. Transplantation, Autologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2006 Mar;132(6):794-5; author reply 795 [16487183.001]
  • [ErratumIn] Br J Haematol. 2006 Mar;132(6):804
  • (PMID = 16197446.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


44. Berger C, Le-Gallo B, Donadieu J, Richard O, Devergie A, Galambrun C, Bordigoni P, Vilmer E, Plouvier E, Perel Y, Michel G, Stephan JL: Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplant; 2005 May;35(10):991-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia.
  • The purpose of this study was to identify risk factors for hypothyroidism after bone marrow transplantation (BMT) for high-risk or relapsed acute lymphoblastic leukaemia (ALL) in children.
  • In all, 388 children with acute lymphoblastic leukaemia underwent allogeneic bone marrow transplantation between 1984 and 1994.
  • Three factors were significantly associated with the onset of hypothyroidism, namely age, bone marrow transplantation in second remission, and single-dose total body irradiation (TBI).
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Hypothyroidism / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


45. Fløisand Y, Brinch L, Dybedal I, Gedde-Dahl T, Heldal D, Holme PA, Egeland T, Tjønnfjord GE: [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia]. Tidsskr Nor Laegeforen; 2008 Nov 20;128(22):2563-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia].
  • BACKGROUND: The success rate for chemotherapy of adults with acute lymphoblastic leukaemia in Norway compares favourably with that in international reports, but improvements are still needed.
  • Allogeneic stem cell transplantation is an option for patients up to 60 years and may contribute to improving the outcome for these patients.
  • MATERIAL AND METHODS: Allogen stem cell transplantation was performed in 61 high-risk patients (38 men and 23 women) with acute lymphoblastic leukaemia at Rikshospitalet between 1985 and 2005.
  • 19 patients were transplanted in first remission and 42 at a later stage of the disease.
  • RESULTS: At the end of 2006, 26 patients (43%) were alive; 21 (35%) in complete remission and 5 with relapse.
  • Estimated 5-year actuarial leukemia-free survival was 35 %.
  • INTERPRETATION: Our results are in line with international reports on the results of allogen stem cell transplantation in high-risk acute lymphoblastic leukaemia.
  • A larger number of patients should be offered such treatment during the first remission than what was the case in the 20-year period this study took place.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Graft vs Host Disease / diagnosis. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Survival Analysis. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023351.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


46. Tajeddine N, Millard I, Gailly P, Gala JL: Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med; 2006;44(5):548-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia.
  • Basal expression of PRAME was determined in 25 blood samples and 25 bone marrow samples from healthy donors, as well as in 12 haematological cell lines (Jurkat, K562, HL60, DOHH2, IM9, Daudi, CEM, KG1, DG75, 8226, U937, Raji).
  • RESULTS: In paediatric acute myeloid leukaemia (AML) (n=22) and acute lymphoblastic leukaemia (ALL) (n=17), and in adult AML (n=20), abnormal PRAME expression was found in 41%, 35% and 40% of cases, respectively.
  • To confirm that PRAME expression was correlated with clinical data, the expression of PRAME was also sequentially followed in patients (n=13) from onset to cytological remission or relapse.
  • CONCLUSIONS: Our data confirm that PRAME quantification by real-time RT-PCR appears suitable for monitoring MRD in PRAME-positive leukaemia.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681423.001).
  • [ISSN] 1434-6621
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / PRAME protein, human
  •  go-up   go-down


47. Ashfaq K, Yahaya I, Hyde C, Andronis L, Barton P, Bayliss S, Chen YF: Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technol Assess; 2010 Dec;14(54):iii-iv, ix-xi, 1-141
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.
  • BACKGROUND: Acute leukaemia is a group of rapidly progressing cancers of bone marrow and blood classified as either acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL).
  • Haemopoietic stem cell transplantation (SCT) has developed as an adjunct to or replacement for conventional chemotherapy with the aim of improving survival and quality of life.
  • OBJECTIVES: A systematic overview of the best available evidence on the clinical effectiveness and cost-effectiveness of SCT in the treatment of acute leukaemia.
  • Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery


48. Offidani M, Corvatta L, Malerba L, Marconi M, Catarini M, Centurioni R, Leoni F, Scortechini AR, Masia MC, Leoni P: Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL). Leuk Lymphoma; 2005 Feb;46(2):233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL).
  • Acute lymphoblastic leukemia (ALL) represents a rare malignancy in the elderly and few authors have specifically focused on the treatment of ALL in this setting.
  • Infectious complications were more frequent with the VDXD combination whereas non-hematological side effects were comparable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Aged. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Female. Humans. Infection / chemically induced. Liposomes / therapeutic use. Male. Middle Aged. Remission Induction / methods. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621806.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


49. Hashmi KU, Khan B, Ahmed P, Raza S, Hussain I, Mahmood A, Iqbal H, Malik HS, Anwar M: FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. J Pak Med Assoc; 2005 Jun;55(6):234-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
  • OBJECTIVE: To evaluate the efficacy and toxicity profile of the combination of fludarabine, high dose cytarabine, idarubicin, and granulocyte colony stimulating factor in refractory relapsed cases of acute leukaemia, a study is being conducted at Armed Forces Bone Marrow Transplant Centre (AFBMTC) Rawalpindi since January 2003.
  • METHODS: Twelve Patients with refractory/relapsed (Ref/Rel) acute leukaemia (AL) were treated with fludarabine 30 mg/m2 and cytosine arabinoside (AraC) Arac 2 g/m2 for 5 days, idarubicin 10 mg/m2 for 3 days, and granulocyte colony stimulating factor G-CSF 5 micro g/kg from day 0 till neutrophil recovery (ANC > 1.0 x 10(9)/1).
  • RESULTS: Patients included were refractory acute lymphoblastic leukaemia (ALL) (n=2), relapsed ALL (n = 3), refractory acute myeloid leukaemia (AML) (n = 3), secondary AML (n=2) relapsed AML (n = 1) and acute undifferentiated leukaemia (AUL) (n = 1).
  • Complete remission (CR) was achieved in 8 (66.6%) patients.
  • Three (25%) patients died of post chemotherapy complications and one patient failed to achieve remission.
  • Out of 8 patients who achieved CR, 4 underwent allogeneic bone marrow transfusion (BMT), 1 is being evaluated for the same, 1 received idorubicin, AraC and etopuside (ICE) and high dose AraC, 1 did not receive further chemotherapy and 1 relapsed two months after remission.
  • CONCLUSION: In our experience, FLAG-IDA is well tolerated and effective regimen in relapsed/refractory acute leukaemias.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Child. Cytarabine / therapeutic use. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Idarubicin / therapeutic use. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045091.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


50. Liu Y, Zhang Y, Hao W, Liu D, Li A, Chen C: Localized residual leukaemia in bone marrow of extremities. Nucl Med Commun; 2008 Jun;29(6):542-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized residual leukaemia in bone marrow of extremities.
  • OBJECTIVE: This study aimed to confirm localized residual leukaemia in the abnormal expanded peripheral bone marrow (e-PBM) of the extremities using Tc-sulfur colloid imaging and bone marrow aspirations.
  • METHODS: Whole-body bone marrow scintigraphy was performed in 420 adult and 48 childhood leukaemia patients using Tc-sulfur colloid (370 MBq).
  • RESULTS: The expansion rate of the PBM in the non-remission stage of acute leukaemia was 73.1%, and it decreased to 38.4% in the complete remission stage.
  • Cytological examination of the e-PBM at the complete remission stage revealed 30.9% localized residual leukaemia.
  • The complete remission period (69+/-23 days) of PBM expansion was significantly greater than that of CBM depletion (43+/-31 days) (P<0.01).
  • Localized residual leukaemia of the e-PBM could not be detected in the childhood acute leukaemia patients and in the patients without e-PBM.
  • The e-PBM is less sensitive to chemotherapy and can easily exist in localized residual leukaemia.
  • The detection of residual leukaemia in the e-PBM by bone marrow scintigraphy is very important in the treatment of leukaemia.
  • [MeSH-major] Bone Marrow Neoplasms / radionuclide imaging. Extremities / radionuclide imaging. Leukemia / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Technetium Tc 99m Sulfur Colloid

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458601.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


51. Rüping MJ, Vehreschild JJ, Cornely OA: Patients at high risk of invasive fungal infections: when and how to treat. Drugs; 2008;68(14):1941-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When and how to treat invasive fungal infections (IFIs) is discussed in this review, with a focus on the two most prevalent non-endemic IFIs, namely invasive aspergillosis and invasive candidiasis.
  • This situation has led to the parallel use of different treatment strategies, e.g. prophylaxis, empirical and pre-emptive treatment, as well as targeted treatment in response to a definite diagnosis of IFI.
  • Patients at risk of invasive aspergillosis comprise (i) those with acute myelogenous leukaemia (AML) or myelodysplastic syndrome (MDS) during remission induction chemotherapy;.
  • (ii) patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT);.
  • Once a diagnosis of invasive aspergillosis has been established, voriconazole should be the preferred treatment option, with LAmB being an alternative.
  • Once a diagnosis has been established, the drug of choice for adequate treatment depends largely on neutrophil count and haemodynamic stability.
  • In non-neutropenic patients, an echinocandin should be considered the first-line treatment option, while patients with susceptible Candida spp. may be switched to fluconazole.
  • LAmB is a second-line treatment option in both settings.Early diagnosis of IFIs is imperative to facilitate treatment success.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2003 Sep 1;37(5):634-43 [12942393.001]
  • [Cites] Diagn Microbiol Infect Dis. 1999 Aug;34(4):281-6 [10459478.001]
  • [Cites] N Engl J Med. 2007 Jan 25;356(4):335-47 [17251530.001]
  • [Cites] Am J Med. 1993 Aug;95(2):177-87 [8395142.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5 [16127033.001]
  • [Cites] Clin Infect Dis. 2008 Jun 15;46(12):1813-21 [18462102.001]
  • [Cites] J Trauma. 1979 Oct;19(10):765-7 [490691.001]
  • [Cites] Clin Infect Dis. 1993 May;16(5):677-88 [8507760.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1519-27 [15070998.001]
  • [Cites] Clin Infect Dis. 2005 Nov 1;41(9):1242-50 [16206097.001]
  • [Cites] Clin Infect Dis. 1997 Jun;24(6):1122-8 [9195068.001]
  • [Cites] J Clin Microbiol. 2004 Jan;42(1):435-8 [14715799.001]
  • [Cites] Clin Infect Dis. 1995 Nov;21(5):1077-89; quiz 1090-1 [8589125.001]
  • [Cites] Clin Infect Dis. 2008 Feb 1;46(3):327-60 [18177225.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):764-71 [10072411.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3489-92 [12202600.001]
  • [Cites] Clin Infect Dis. 2006 Jul 1;43(1):25-31 [16758414.001]
  • [Cites] Blood. 2003 May 1;101(9):3365-72 [12393455.001]
  • [Cites] N Engl J Med. 2004 Sep 30;351(14 ):1391-402 [15459300.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Clin Infect Dis. 2006 Apr 1;42(7):955-63 [16511759.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):221-9 [12856215.001]
  • [Cites] Clin Infect Dis. 2005 Jul 1;41(1):52-9 [15937763.001]
  • [Cites] Ann Hematol. 2003 Oct;82 Suppl 2:S118-26 [13680172.001]
  • [Cites] Lancet. 2005 Oct 22-28;366(9495):1435-42 [16243088.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Feb;49(2):512-7 [15673726.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):278-80 [11807153.001]
  • [Cites] N Engl J Med. 2007 Jun 14;356(24):2472-82 [17568028.001]
  • [Cites] Arch Surg. 1991 Jan;126(1):44-8 [1985634.001]
  • [Cites] Transplantation. 2004 Apr 27;77(8):1260-4 [15114095.001]
  • [Cites] J Infect Dis. 2000 Jan;181(1):309-16 [10608780.001]
  • [Cites] Expert Opin Pharmacother. 2008 Feb;9(2):175-91 [18201143.001]
  • [Cites] Arch Surg. 1971 May;102(5):476-82 [5580338.001]
  • [Cites] J Antimicrob Chemother. 2006 Feb;57(2):317-25 [16339606.001]
  • [Cites] Clin Infect Dis. 2008 Aug 1;47(3):427; author reply 427-8 [18605908.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):225-34 [11807146.001]
  • [Cites] Surg Infect (Larchmt). 2003 Winter;4(4):345-54 [15012861.001]
  • [Cites] Ann Intern Med. 2001 Sep 18;135(6):412-22 [11560454.001]
  • [Cites] J Infect Dis. 1995 Jun;171(6):1545-52 [7769290.001]
  • [Cites] Clin Infect Dis. 2001 Jul 15;33(2):177-86 [11418877.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):156-61 [12614732.001]
  • [Cites] Lancet. 2007 May 5;369(9572):1519-27 [17482982.001]
  • [Cites] Intensive Care Med. 2005 Nov;31(11):1479-87 [16172847.001]
  • [Cites] Clin Infect Dis. 2002 Apr 1;34(7):909-17 [11880955.001]
  • [Cites] J Clin Microbiol. 2006 Feb;44(2):529-35 [16455909.001]
  • [Cites] Clin Infect Dis. 2003 Nov 1;37(9):1172-7 [14557960.001]
  • [Cites] Clin Infect Dis. 2005 Sep 15;41 Suppl 6:S389-93 [16108005.001]
  • [Cites] Clin Infect Dis. 2007 Feb 1;44(3):373-9 [17205443.001]
  • [Cites] Radiology. 1985 Dec;157(3):611-4 [3864189.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2928-36 [16720833.001]
  • [Cites] Crit Care. 2006;10(2):132 [16584528.001]
  • [Cites] Crit Care Med. 2003 Mar;31(3):752-7 [12626979.001]
  • [Cites] Clin Microbiol Rev. 2005 Jan;18(1):44-69 [15653818.001]
  • [Cites] Am J Transplant. 2004 May;4(5):796-802 [15084177.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1604-10 [11238098.001]
  • [Cites] N Engl J Med. 1992 Mar 26;326(13):845-51 [1542320.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3142-6 [15243073.001]
  • [Cites] J Clin Microbiol. 2006 Mar;44(3):760-3 [16517851.001]
  • [Cites] Lancet Infect Dis. 2005 Oct;5(10):609-22 [16183515.001]
  • [Cites] Medicine (Baltimore). 2003 Sep;82(5):309-21 [14530780.001]
  • [Cites] Intensive Care Med. 2002 Dec;28(12):1708-17 [12447512.001]
  • [Cites] J Clin Microbiol. 2005 Sep;43(9):4434-40 [16145088.001]
  • [Cites] Arch Intern Med. 1989 Oct;149(10):2349-53 [2802900.001]
  • [Cites] Lancet Infect Dis. 2003 Nov;3(11):685-702 [14592598.001]
  • [Cites] Clin Diagn Lab Immunol. 2003 Sep;10(5):882-5 [12965921.001]
  • [Cites] Clin Infect Dis. 1999 Nov;29(5):1164-70 [10524958.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1068-75 [16885047.001]
  • [Cites] J Clin Microbiol. 2007 Jun;45(6):1735-45 [17442797.001]
  • [Cites] Clin Infect Dis. 2000 Aug;31(2):545-53 [10987719.001]
  • [Cites] Transpl Infect Dis. 1999 Dec;1(4):229-36 [11428994.001]
  • [Cites] Clin Infect Dis. 2001 Oct 15;33(8):e83-90 [11550120.001]
  • [Cites] Am J Med. 1994 Aug;97(2):135-44 [8059779.001]
  • [Cites] J Infect. 2007 Nov;55(5):445-9 [17822770.001]
  • [Cites] Transpl Infect Dis. 2007 Mar;9(1):3-10 [17313464.001]
  • [Cites] Liver Transpl. 2006 May;12(5):850-8 [16628697.001]
  • [Cites] Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5 [9564455.001]
  • [Cites] Ann Surg. 1994 Dec;220(6):751-8 [7986142.001]
  • [Cites] Br J Haematol. 2006 Jan;132(1):3-12 [16371014.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] Medicine (Baltimore). 2000 Jul;79(4):250-60 [10941354.001]
  • [Cites] N Engl J Med. 1994 Nov 17;331(20):1325-30 [7935701.001]
  • [Cites] J Clin Microbiol. 2005 Apr;43(4):1829-35 [15815004.001]
  • [Cites] J Infect. 1991 Jan;22(1):45-52 [1848268.001]
  • [Cites] Clin Infect Dis. 2004 Nov 15;39(10):1407-16 [15546073.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2007 Apr;26(4):271-6 [17333081.001]
  • [Cites] Crit Care Med. 2004 Dec;32(12):2443-9 [15599149.001]
  • [Cites] Clin Microbiol Rev. 2007 Jan;20(1):133-63 [17223626.001]
  • [Cites] J Hosp Infect. 2002 Aug;51(4):297-304 [12183145.001]
  • [Cites] Ann Surg. 2001 Apr;233(4):542-8 [11303137.001]
  • [Cites] Emerg Infect Dis. 2004 Oct;10 (10 ):1713-20 [15504255.001]
  • [Cites] J Antimicrob Chemother. 2003 Jul;52(1):71-7 [12775680.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):22-8 [16173959.001]
  • [Cites] J Infect Dis. 2002 Nov 1;186(9):1297-306 [12402199.001]
  • [Cites] Med Mycol. 2005 May;43(3):235-43 [16010850.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4358-66 [12393425.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):408-15 [12167683.001]
  • [Cites] J Clin Microbiol. 2006 Jun;44(6):1977-81 [16757587.001]
  • [Cites] Crit Care Med. 2006 Mar;34(3):730-7 [16505659.001]
  • [Cites] J Antimicrob Chemother. 2005 Sep;56(3):532-7 [16040623.001]
  • [Cites] Clin Infect Dis. 2007 May 15;44(10):1289-97 [17443465.001]
  • [Cites] Clin Infect Dis. 2004 Aug 1;39(3):309-17 [15306996.001]
  • [Cites] Intensive Care Med. 2007 Oct;33(10):1679-81 [17646965.001]
  • [Cites] Clin Infect Dis. 2007 Oct 1;45(7):883-93 [17806055.001]
  • [Cites] Clin Infect Dis. 2001 Apr 15;32(8):1191-200 [11283809.001]
  • [Cites] Antimicrob Agents Chemother. 2007 May;51(5):1818-21 [17307977.001]
  • [Cites] Clin Infect Dis. 2004 Feb 1;38(3):311-20 [14727199.001]
  • [Cites] Infect Control Hosp Epidemiol. 2004 Aug;25(8):624-6 [15357151.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):2020-9 [12490683.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Nov;49(11):4555-60 [16251295.001]
  • [Cites] Liver Transpl. 2005 Jun;11(6):656-62 [15915482.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2004 Oct;23(10):739-44 [15372315.001]
  • [Cites] Crit Care Med. 1999 Jun;27(6):1066-72 [10397206.001]
  • [Cites] J Clin Microbiol. 2002 Apr;40(4):1298-302 [11923348.001]
  • [Cites] Emerg Infect Dis. 2003 Aug;9(8):985-90 [12967498.001]
  • [Cites] N Engl J Med. 2007 Dec 20;357(25):2601-14 [18094380.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Sep 15;170(6):621-5 [15229094.001]
  • [Cites] Am J Transplant. 2004 Nov;4 Suppl 10:110-34 [15504225.001]
  • [Cites] Curr Opin Infect Dis. 2006 Dec;19(6):571-6 [17075333.001]
  • [Cites] Drug Resist Updat. 2007 Jun;10(3):121-30 [17569573.001]
  • [Cites] Crit Care. 2006 Feb;10(1):R31 [16507158.001]
  • [Cites] Liver Transpl. 2002 Nov;8(11):1065-70 [12424722.001]
  • [Cites] N Engl J Med. 2007 Jan 25;356(4):348-59 [17251531.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2003 Aug;22(8):457-62 [12898283.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):797-804 [7889948.001]
  • [Cites] J Antimicrob Chemother. 2006 Apr;57(4):628-38 [16459344.001]
  • [Cites] Diagn Microbiol Infect Dis. 2008 Mar;60(3):273-7 [18024053.001]
  • [Cites] Ann Hematol. 2003 Oct;82 Suppl 2:S105-17 [13680173.001]
  • [Cites] N Engl J Med. 2002 May 30;346(22):1745-7; author reply 1745-7 [12041526.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Oct;13(10):1192-200 [17889356.001]
  • [Cites] J Hosp Infect. 2002 Aug;51(4):288-96 [12183144.001]
  • [Cites] J Heart Lung Transplant. 2003 Mar;22(3):258-66 [12633692.001]
  • [Cites] Drugs. 2007;67(11):1567-601 [17661528.001]
  • [Cites] Clin Microbiol Infect. 2008 May;14 Suppl 4:65-70 [18430131.001]
  • [Cites] Clin Microbiol Infect. 2002 Jul;8(7):405-12 [12199850.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):475-82 [11841455.001]
  • [Cites] J Clin Microbiol. 2008 Mar;46(3):842-9 [18199791.001]
  • (PMID = 18778118.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 141
  •  go-up   go-down


52. Benson RE, Rodd HD, North S, Loescher AR, Farthing PM, Payne M: Leukaemic infiltration of the mandible in a young girl. Int J Paediatr Dent; 2007 Mar;17(2):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: The patient was in remission from acute lymphoblastic leukaemia when she presented with pain localized to the alveolar ridge overlying the unerupted lower right second permanent molar.
  • Biopsy confirmed leukaemia recurrence demonstrating the Philadelphia chromosome.
  • CONCLUSION: The importance of regular and long-term dental examination of patients with leukaemia is discussed.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263867.001).
  • [ISSN] 0960-7439
  • [Journal-full-title] International journal of paediatric dentistry
  • [ISO-abbreviation] Int J Paediatr Dent
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 7S5I7G3JQL / Dexamethasone; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


53. Buccisano F, Maurillo L, Tamburini A, Del Poeta G, Del Principe MI, Ammatuna E, Consalvo MI, Campagna S, Ottaviani L, Sarlo C, Renzi D, Faccia S, Fraboni D, Lo Coco F, Amadori S, Venditti A: Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes. Eur J Haematol; 2008 Feb;80(2):107-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: An aberrant pattern of expression of L-selectin and intercellular adhesion molecule 1 (ICAM1) may characterise CD34+ blast cells in myelodysplastic syndromes (MDS) and secondary acute myeloid leukaemia (sAML).
  • Furthermore, in two patients a decrease of the ratio was observed when overt leukaemic transformation occurred; conversely, restoration of a normal ratio was observed in two patients after a chemotherapy-induced remission.
  • CONCLUSION: (i) L-selectin is defective in the stem cell compartment of MDS and sAML, whereas ICAM1 is overexpressed;.
  • (ii) the ratio of their expression has a prognostic role; and (iii) a ratio <1 significantly predicts progression to overt leukaemia in MDS patients.
  • [MeSH-major] Gene Expression Regulation. Intercellular Adhesion Molecule-1 / biosynthesis. L-Selectin / biosynthesis. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / biosynthesis. Bone Marrow / metabolism. Disease Progression. Female. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / metabolism. Male. Middle Aged. Prognosis. Time Factors


54. Curley C, Kennedy G, Haughton A, Love A, McCarthy C, Boyd A: Acute myeloid leukemia, the 3q21q26 syndrome and diabetes insipidus: a case presentation. Asia Pac J Clin Oncol; 2010 Jun;6(2):77-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia, the 3q21q26 syndrome and diabetes insipidus: a case presentation.
  • Diabetes insipidus (DI) is a rare presenting complication of acute myeloid leukaemia (AML).
  • Typically, the combination of DI and AML is associated with structural abnormalities of the neurohypophysis.
  • We present a case of AML and DI presenting without any abnormalities of the neurohypophysis on radiological scanning and with normal cerebrospinal fluid examination.
  • After treatment with induction chemotherapy, the patient achieved a complete remission and his DI resolved.
  • q26) translocation or monosomy 7, DI did not recur.
  • q26) translocation and/or monosomy 7 in AML may directly result in dysregulation of transcription factors resulting in development of DI in AML patients.
  • [MeSH-major] Chromosomes, Human, Pair 3. Diabetes Insipidus / complications. Diabetes Insipidus / genetics. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / genetics


55. Breems DA, Boogaerts MA, Dekker AW, Van Putten WL, Sonneveld P, Huijgens PC, Van der Lelie J, Vellenga E, Gratwohl A, Verhoef GE, Verdonck LF, Löwenberg B: Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol; 2005 Jan;128(1):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial.
  • The question as to whether autologous stem cell transplantation (SCT) after consolidation chemotherapy improves the probability of survival of patients with acute myeloid leukaemia (AML) in first remission has not been settled.
  • Patients who had reached a complete remission (CR) after two courses of induction chemotherapy and who were not eligible for a human leucocyte antigen-matched sibling SCT (n = 130), were randomized after a third consolidation cycle of chemotherapy between high-dose cytotoxic treatment and autologous bone marrow transplantation or no further treatment.
  • [MeSH-major] Leukemia, Myeloid / surgery. Stem Cell Transplantation
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Belgium. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Netherlands. Prospective Studies. Remission Induction. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Bone Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606550.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


56. Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, Qian J, Jin J, Xu H: Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol; 2009 Nov;158(2):199-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia.
  • T helper type 17 (Th17) cells, which represent a novel subset of CD4(+) T cells, play an active role in inflammatory and autoimmune diseases.
  • In this study, we investigated Th17 cell frequency and secretion of related cytokines in patients with acute myeloid leukaemia (AML).
  • First, we found that Th17 cell frequencies were increased significantly in peripheral blood samples from untreated patients with AML, compared with those from healthy volunteers.
  • Moreover, increased interleukin (IL)-17 concentrations accompanied the increased Th17 cell frequencies in these patients.
  • Secondly, we found that the increased Th17 cell frequencies were reduced when patients achieved complete remission after chemotherapy, suggesting that measurement of Th17 cell frequencies may have clinical value in the evaluation of therapeutic effect.
  • In addition, we found that IL-6 and transforming growth factor (TGF)-beta1 concentrations increased in the untreated patients and that IL-6 concentrations showed a positive correlation with the frequencies of Th17 cells, suggesting that IL-6 may play an important role in Th17 cell differentiation in patients with AML.
  • [MeSH-major] Interleukin-17 / blood. Leukemia, Myeloid, Acute / immunology. T-Lymphocyte Subsets / immunology. T-Lymphocytes, Helper-Inducer / immunology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Flow Cytometry / methods. Humans. Interleukin-6 / blood. Male. Middle Aged. Remission Induction. Transforming Growth Factor beta / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 2001 Jun;56(6):487-93 [11359967.001]
  • [Cites] Blood. 2001 Feb 1;97(3):624-30 [11157477.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2620-7 [12411307.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):452-5 [14744755.001]
  • [Cites] J Cell Mol Med. 2003 Oct-Dec;7(4):472-4 [14754516.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] AIDS. 1990 Apr;4(4):367-8 [2350458.001]
  • [Cites] Exp Cell Res. 1992 Jul;201(1):160-73 [1612121.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2457-64 [15781662.001]
  • [Cites] Int Arch Allergy Immunol. 2005;137 Suppl 1:51-4 [15947485.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] J Leukoc Biol. 2005 Oct;78(4):946-53 [16033813.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6177-89 [16237115.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] Eur J Haematol. 2005 Dec;75(6):468-76 [16313258.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] Immunity. 2006 Feb;24(2):179-89 [16473830.001]
  • [Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]
  • [Cites] Nature. 2006 May 11;441(7090):231-4 [16648837.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] Cell. 2006 Sep 22;126(6):1121-33 [16990136.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2817-29 [16947782.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6730-3 [17513719.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):950-7 [17676044.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):2936-46 [17763419.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3804-13 [17693581.001]
  • [Cites] Immunity. 2008 Apr;28(4):445-53 [18400187.001]
  • [Cites] Nat Immunol. 2008 Jun;9(6):650-7 [18454150.001]
  • [Cites] Nat Immunol. 2008 Jun;9(6):641-9 [18454151.001]
  • [Cites] Blood. 2008 Jul 15;112(2):362-73 [18354038.001]
  • [Cites] Nature. 2008 Jul 17;454(7202):350-2 [18469800.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 26;374(3):533-7 [18655770.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):942-9 [17676045.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):933-44 [12461566.001]
  • (PMID = 19737137.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-17; 0 / Interleukin-6; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2768809
  •  go-up   go-down


57. Klammer M, Waterfall M, Samuel K, Turner ML, Roddie PH: Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br J Haematol; 2005 May;129(3):340-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
  • We assessed the potential of tumour cell/dendritic cell fusion hybrids to generate in vitro anti-leukaemic T-cell responses following co-culture with autologous remission lymphocytes in six patients with acute myeloid leukaemia (AML).
  • Fusion hybrids induced anti-leukaemic T-cell immune responses in three of six patients.
  • Only one of six patients remission lymphocytes failed to develop leukaemia-directed immune responses following stimulation with either construct.
  • Anti-proliferative properties of fusion hybrids against allogeneic lymphocytes were observed in mixed lymphocyte-leukaemia reactions and were found not to be specific to the cell fusion partners and did not prevent the ability of AML-mDC heterokaryons to induce autologous anti-leukaemic cytotoxicity.
  • We conclude that tumour cell/dendritic cell fusion hybrids hold promise as a cellular vaccine for AML.
  • [MeSH-major] Cancer Vaccines / immunology. Dendritic Cells / immunology. Leukemia, Myeloid / immunology
  • [MeSH-minor] Acute Disease. Adult. Aged. Cell Fusion. Cell Proliferation. Coculture Techniques. Cytotoxicity, Immunologic. Female. Flow Cytometry. Humans. Immunophenotyping. Lymphocyte Activation / immunology. Lymphocyte Culture Test, Mixed. Male. Microscopy, Fluorescence. Middle Aged. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842657.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


58. Chevallier P, Mahe B, Garand R, Talmant P, Harousseau JL, Delaunay J: Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. Int J Hematol; 2008 Sep;88(2):209-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
  • It was developed at the end of the nineties as 90% of the leukemic blast population of patients with acute myeloid leukaemia (AML) express the CD33 surface antigen (Dinndorf et al. [1] Blood 1986;67:1048-53).
  • CD33 antigen expression is also observed at diagnosis (in 15% of cases) (Pui et al. [3] J Clin Oncol 1998;16:3768-73) or at relapse (Guglielmi et al. [4] Leukemia 1997; 11:1501-7) of acute lymphoblastic leukaemia (ALL), representing a potential cellular target for ALL patients.
  • Case series have already demonstrated the efficacy of GO in children with relapsed CD33+ ALL with documentation of complete remission (CR) (Balduzzi et al. [5] Leukemia 2003;17:2247-8; Cotter et al. [6] Br J Haematol 2003;122:686-91; Zwaan et al. [7] Leukemia 2003;17:468-70).
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Fatal Outcome. Hematopoietic Stem Cell Transplantation. Humans. Male. Remission Induction. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2004 Nov;89(11):1399-401 [15531467.001]
  • [Cites] Leukemia. 2003 Feb;17 (2):468-70 [12592351.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3768-73 [9850020.001]
  • [Cites] Blood. 1986 Apr;67(4):1048-53 [2937468.001]
  • [Cites] Br J Haematol. 2007 Oct;139(2):344-5 [17897313.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1003-7 [16038726.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Br J Haematol. 2003 Aug;122(4):687-8 [12899727.001]
  • [Cites] Leukemia. 2004 Sep;18(9):1557-8 [15229619.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2247-8 [12960967.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1501-7 [9305605.001]
  • (PMID = 18668307.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 93NS566KF7 / gemtuzumab
  •  go-up   go-down


59. Nevill TJ, Hogge DE, Toze CL, Nantel SH, Power MM, Abou Mourad YR, Song KW, Lavoie JC, Forrest DL, Barnett MJ, Shepherd JD, Nitta JY, Wong S, Sutherland HJ, Smith CA: Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML. Bone Marrow Transplant; 2008 Nov;42(10):659-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Administration of alkylating agents (Alk), topoisomerase II inhibitors (Topo II) and radiotherapy (RT) can result in therapy-related myelodysplastic syndrome or acute myelogenous leukaemia (t-MDS/t-AML), the optimal treatment for which is allo-SCT.
  • Eight patients remain alive and in continuous remission (median follow-up 54 months (range, 12-161)) with estimated 5-year EFS being 30% (95% confidence intervals 16-58%).
  • Corresponding actuarial risks of relapse and non-relapse mortality (NRM) are 39% (19-60%) and 30% (13-50%), respectively.
  • In multivariate analysis, development of acute GVHD (P=0.009) and Topo II-related t-MDS/t-AML (P=0.018) were associated with inferior EFS.
  • Patients with acute GVHD had an increased risk of NRM (P=0.03) whereas risk of relapse was higher for patients of advanced age (P=0.046) and for patients who underwent bone marrow (vs blood) SCT (P=0.032).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Myeloablative Agonists / adverse effects. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / therapy


60. Reinfjell T, Lofstad GE, Veenstra M, Vikan A, Diseth TH: Health-related quality of life and intellectual functioning in children in remission from acute lymphoblastic leukaemia. Acta Paediatr; 2007 Sep;96(9):1280-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life and intellectual functioning in children in remission from acute lymphoblastic leukaemia.
  • AIM: To evaluate the health-related quality of life (HRQOL) and intellectual functioning of children in remission from acute lymphoblastic leukaemia (ALL).
  • Follow-up programs that target the psychosocial health of children in remission from ALL should be implemented.
  • [MeSH-major] Cognition / physiology. Health Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Quality of Life / psychology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Neuropsychological Tests. Remission Induction. Surveys and Questionnaires

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Paediatr. 2007 Sep;96(9):1265-8 [17718778.001]
  • (PMID = 17590194.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


61. Min WS, Kim HJ, Choi Y, Jeong HY, Kim CC: Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients. Hematol Oncol; 2007 Jun;25(2):76-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients.
  • To correlate clinical outcomes with the expression of interleukin-2 receptor alpha (CD25) positive cells during induction chemotherapy (IC) in adult patients with acute myeloid leukaemia (AML), we investigated the prognostic importance of subsets of peripheral blood (PB) CD45+CD25+ cells.
  • The gated CD45/CD25 cell populations were used to compare the intensity of immunophenotypic signals based on the treatment timeline.
  • In addition, patients in complete remission (CR) (n = 61) demonstrated relatively lower levels of steady PB CD45+CD25+ after standard IC.
  • [MeSH-major] Interleukin-2 Receptor alpha Subunit / analysis. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 John Wiley & Sons, Ltd.
  • (PMID = 17200986.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


62. Ottmann OG, Pfeifer H: First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol; 2009 Jun;21 Suppl 1:S43-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.
  • The tyrosine kinase inhibitor (TKI) imatinib has become an integral part of front-line therapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia, with remission rates exceeding 90% irrespective of whether imatinib is given alone or combined with chemotherapy.
  • Treatment outcome with imatinib-based regimens has improved compared with historic controls, but most patients who do not undergo allogeneic stem cell transplantation (SCT) eventually relapse.
  • [MeSH-major] Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Benzamides. Combined Modality Therapy. Dasatinib. Humans. Imatinib Mesylate. Mutation. Piperazines / administration & dosage. Protein Kinase Inhibitors / administration & dosage. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / administration & dosage. Stem Cell Transplantation. Thiazoles / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561414.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; RBZ1571X5H / Dasatinib
  • [Number-of-references] 26
  •  go-up   go-down


63. Harani MS, Adil SN, Kakepoto GN, Khilji Z, Shaikh U, Khurshid M: Significance of cytogenetic abnormalities in acute myeloid leukaemia. J Pak Med Assoc; 2006 Jan;56(1):9-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of cytogenetic abnormalities in acute myeloid leukaemia.
  • OBJECTIVE: To evaluate the role of karyotype in acute myeloid leukaemia (AML) as a predictor of response to induction chemotherapy.
  • Diagnosis of AML was based on FAB criteria, immunophenotyping and cytogenetic studies.
  • They were treated according to standard protocols (combination of anthracycline and cytarabine -3+7) and those who had acute promyelocytic leukaemia additionally received all- trans retinoic acid (ATRA).
  • Half of the (51.2%) patients out of remaining 41 achieved complete remission on bone marrow examination after receiving induction chemotherapy.
  • In favourable risk group 3/3 (100%) achieved complete remission (CR) while 15/32 (46.9%) in intermediate risk group and 3/6 (50%) in unfavourable risk group.
  • There was low CR rate in patients with high white cell counts.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454127.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


64. Béné MC: Immunophenotyping of acute leukaemias. Immunol Lett; 2005 Apr 15;98(1):9-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping of acute leukaemias.
  • Progress in the management and understanding of acute leukaemia can only be obtained if these diseases are thoroughly investigated, both clinically and with a series of biological tools.
  • This alone has made and still will make possible the identification of prognostic factors and of useful markers for the follow-up of patients in remission.
  • Among the variety of approaches of acute leukaemia definition, immunophenotyping has taken over the past 25 years a predominant and now well-defined place, although room is left for further improvement.
  • In this review, the current state-of-the-art of immunophenotyping of acute leukaemias will be replaced in the context of physiological leukocyte maturation.
  • [MeSH-major] Immunophenotyping. Leukemia, Myeloid, Acute / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Animals. Antigens, Differentiation, B-Lymphocyte / immunology. Antigens, Differentiation, T-Lymphocyte / immunology. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Cell Lineage / immunology. Humans. Myeloid Cells / immunology. Myeloid Cells / pathology. T-Lymphocytes / immunology. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790504.001).
  • [ISSN] 0165-2478
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antigens, Differentiation, T-Lymphocyte
  • [Number-of-references] 62
  •  go-up   go-down


65. Ridola V, Buonuomo PS, Maurizi P, Putzulu R, Annunziata ML, Pietrini D, Riccardi R: Severe acute hypertriglyceridemia during acute lymphoblastic leukemia induction successfully treated with plasmapheresis. Pediatr Blood Cancer; 2008 Feb;50(2):378-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe acute hypertriglyceridemia during acute lymphoblastic leukemia induction successfully treated with plasmapheresis.
  • Children suffering from Acute Lymphoblastic Leukaemia (ALL) treated with asparaginase and corticosteroids are at risk of developing severe lipid abnormalities.
  • [MeSH-major] Hypertriglyceridemia / therapy. Plasmapheresis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Combined Modality Therapy. Humans. Leukapheresis. Male. Remission Induction. Triglycerides / blood

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Triglycerides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16883590.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Triglycerides; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


66. Feltbower RG, Kinsey SE, Richards M, Shenton G, Michelagnoli MP, McKinney PA: Survival following relapse in childhood haematological malignancies diagnosed in 1974-2003 in Yorkshire, UK. Br J Cancer; 2007 Apr 10;96(7):1147-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leukaemia patients from more deprived areas were significantly less likely to relapse (odds ratio=0.54, 95% confidence interval 0.32-0.93 for most deprived quintile vs least deprived quintile; P(trend)=0.06), especially those with acute myeloid leukaemia (P=0.04).
  • Length of first remission was a strong predictor of survival for leukaemia with a 46% reduced risk of death for every additional year of event-free survival.
  • [MeSH-major] Hematologic Neoplasms / mortality. Neoplasm Recurrence, Local / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2247-56 [11187916.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2257-66 [11187917.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2295-306 [11187921.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2307-20 [11187922.001]
  • [Cites] J Public Health Med. 1999 Dec;21(4):401-6 [11469361.001]
  • [Cites] Lancet. 2001 Aug 4;358(9279):385-7 [11502322.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Acta Paediatr Scand. 1987 Sep;76(5):781-8 [3477938.001]
  • [Cites] Br J Cancer. 1990 Nov;62(5):806-15 [2173943.001]
  • [Cites] Med Pediatr Oncol. 1992;20(4):315-20 [1318996.001]
  • [Cites] BMJ. 1994 Jul 16;309(6948):162-6 [8044095.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):372-8 [7674994.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):423-38 [9695956.001]
  • [Cites] BMJ. 1999 Mar 27;318(7187):843-4 [10092262.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2025-9 [16304569.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2090-100 [16304571.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • (PMID = 17342086.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360123
  •  go-up   go-down


67. Khanim FL, Bradbury CA, Arrazi J, Hayden RE, Rye A, Basu S, MacWhannell A, Sawers A, Griffiths M, Cook M, Freeman S, Nightingale KP, Grimwade D, Falciani F, Turner BM, Bunce CM, Craddock C: Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Br J Haematol; 2009 Feb;144(3):332-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histone deacetylase inhibitors (HDIs) are emerging as valuable new agents in the treatment of acute myeloid leukaemia (AML).
  • In a trial of 20 patients treated with the HDI sodium valproate (VPA) in combination with all trans retinoic acid and theophylline, three patients responded clinically with one complete remission (CR) and two partial remissions.
  • Microarray analysis of the primary AMLs and a panel of haemato-lymphoid cell lines, with a similar range of VPA sensitivities as the primary leukaemic blasts, identified elevated FOSB-expression as a potential marker of VPA sensitivity.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Leukemic. Histone Deacetylases / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Proto-Oncogene Proteins c-fos / genetics. Valproic Acid / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Blotting, Western. Cell Line, Tumor. Female. Gene Expression. Gene Expression Profiling / methods. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036090.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOSB protein, human; 0 / Proto-Oncogene Proteins c-fos; 614OI1Z5WI / Valproic Acid; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


68. Buda G, Romagnoli MC, Galimberti S, Figus M, Papineschi F, Nardi M, Petrini M: Simultaneous appearance of acute myeloid leukemia in a patient with bilateral primary uveal melanoma. Melanoma Res; 2006 Oct;16(5):467-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous appearance of acute myeloid leukemia in a patient with bilateral primary uveal melanoma.
  • We report a rare case of a patient with bilateral uveal melanoma (the first eye surgically treated 6 years before the occurrence of melanoma in the contralateral eye), who developed an acute myeloid leukaemia.
  • [MeSH-major] Eye Neoplasms / complications. Eye Neoplasms / diagnosis. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis. Melanoma / complications. Melanoma / diagnosis. Neoplasms, Second Primary / diagnosis. Uveal Neoplasms / complications. Uveal Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Middle Aged. Remission Induction. Treatment Outcome


69. Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M, Ethell M, Morgan G, Singhal S, Mehta J: The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients. Bone Marrow Transplant; 2008 Jul;42(2):105-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients.
  • Age 30 years, >4 weeks to attain remission, and karyotypes t(4;11) and t(9;22) were associated with adverse outcome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


70. Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B, Iversen PO: Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia; 2009 Jan;23(1):162-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hence, we measured bone marrow microvessel density (MVD), plasma concentrations of eight angiogenesis-related parameters and the expression in blood mononuclear cells of 40 angiogenesis-related mRNAs in 93 patients with haematological neoplasias (acute myeloid leukaemia; chronic lymphatic leukaemia; multiple myeloma (MM); or non-Hodgkin's lymphoma (NHL)) before start and after completion of cancer therapy.
  • VEGF levels were highest in those who did not achieve complete remission after cancer therapy.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18800145.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Interleukin-6; 0 / Interleukin-8; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


71. Mylonakis ME, Petanides TA, Valli VE, Vernau W, Koytinas AF, Michael RS: Acute myelomonocytic leukaemia with short-term spontaneous remission in a cat. Aust Vet J; 2008 Jun;86(6):224-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelomonocytic leukaemia with short-term spontaneous remission in a cat.
  • A complete blood count (CBC) and a biochemistry profile showed leukocytosis, numerous blast cells in the peripheral blood, thrombocytopenia, hyperglobulinaemia and a positive test for feline leukaemia virus antigen.
  • A diagnosis of acute myelomonocytic leukaemia was made on the basis of the results of bone marrow cytology, histopathology, and immunochemistry (CD3, CD79a, lysozyme, and myeloperoxidase) tests.
  • Following an unexpected 1-month period of clinical and clinicopathological remission without chemotherapy, the cat relapsed and died 1 week later.
  • [MeSH-major] Cat Diseases / diagnosis. Leukemia, Myelomonocytic, Acute / veterinary. Neoplasm Regression, Spontaneous
  • [MeSH-minor] Animals. Anorexia / etiology. Anorexia / veterinary. Blood Cell Count / veterinary. Bone Marrow Cells / pathology. Cats. Fatal Outcome. Female. Weight Loss

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498558.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


72. Ragusa M, Avola G, Angelica R, Barbagallo D, Guglielmino MR, Duro LR, Majorana A, Statello L, Salito L, Consoli C, Camuglia MG, Di Pietro C, Milone G, Purrello M: Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy. BMC Cancer; 2010;10:377
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.
  • BACKGROUND: According to the different sensitivity of their bone marrow CD34+ cells to in vitro treatment with Etoposide or Mafosfamide, Acute Myeloid Leukaemia (AML) patients in apparent complete remission (CR) after chemotherapy induction may be classified into three groups: (i) normally responsive;.
  • CONCLUSIONS: AM genes represent critical nodes for the proper execution of cell death following pharmacological induction in patients.
  • We propose that their dysregulation (either due to inborn or de novo genomic mutations selected by treatment) could cause a relapse in apparent CR AML patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis. Biomarkers, Tumor / genetics. Bone Marrow Cells / metabolism. Drug Resistance, Neoplasm / genetics. Gene Expression Profiling. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Adult. Antigens, CD34 / metabolism. Cell Movement. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm, Residual / drug therapy. Neoplasm, Residual / genetics. Neoplasm, Residual / pathology. Oligonucleotide Array Sequence Analysis. Prospective Studies. RNA, Messenger / genetics. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1993 Jul 1;82(1):15-21 [8324219.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Dec;41(12):2372-5 [19699815.001]
  • [Cites] Oncogene. 2006 Feb 9;25(6):838-48 [16247474.001]
  • [Cites] Mayo Clin Proc. 2006 Feb;81(2):247-60 [16471082.001]
  • [Cites] Toxicol Sci. 2006 Aug;92(2):587-95 [16675512.001]
  • [Cites] CA Cancer J Clin. 1996 May-Jun;46(3):165-84 [8646546.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2048-59 [9058727.001]
  • [Cites] Leukemia. 1998 Mar;12(3):382-9 [9529133.001]
  • [Cites] Leuk Res. 1998 Jun;22(6):557-60 [9678722.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] J Leukoc Biol. 2004 Nov;76(5):1047-56 [15328334.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):682-6 [15861191.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4770-4 [16000573.001]
  • [Cites] Med Princ Pract. 2005;14 Suppl 1:35-48 [16103712.001]
  • [Cites] Br J Haematol. 2000 Jun;109(3):611-5 [10886211.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):21-6 [11148681.001]
  • [Cites] Curr Opin Oncol. 2001 Nov;13(6):463-9 [11673686.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3284-94 [12032770.001]
  • [Cites] Leukemia. 2003 Jan;17(1):60-7 [12529661.001]
  • [Cites] Leukemia. 2003 Jan;17(1):68-75 [12529662.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):434-41 [12580957.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Genome Res. 2003 Nov;13(11):2498-504 [14597658.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3657-61 [14666661.001]
  • [Cites] Leukemia. 2004 Jan;18(1):1-10 [14574330.001]
  • [Cites] Leukemia. 2004 Feb;18(2):358-60 [14628070.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26915-21 [15078892.001]
  • [Cites] J Clin Immunol. 2004 Sep;24(5):553-60 [15359114.001]
  • [Cites] Blood Rev. 2006 Nov;20(6):333-42 [16920238.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:169-77 [17124057.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Curr Pharm Des. 2006;12(34):4411-25 [17168751.001]
  • [Cites] Acta Haematol. 2007;117(1):8-15 [17095854.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):209-17 [17224646.001]
  • [Cites] Exp Hematol. 2007 Jun;35(6):957-66 [17533050.001]
  • [Cites] Bioinformatics. 2007 Sep 15;23(18):2495-7 [17644818.001]
  • [Cites] Mol Syst Biol. 2007;3:152 [18091723.001]
  • [Cites] Bioinformatics. 2008 Jan 15;24(2):282-4 [18006545.001]
  • [Cites] Cell Biol Int. 2008 Mar;32(3):329-36 [18243739.001]
  • [Cites] Blood. 2008 Apr 15;111(8):3923-30 [18398055.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2519-26 [18451212.001]
  • [Cites] Pharmacology. 2008;81(4):275-300 [18259091.001]
  • [Cites] Br J Haematol. 2008 Jul;142(1):74-8 [18422993.001]
  • [Cites] Leuk Res. 2008 Nov;32(11):1684-97 [18339423.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):365-77 [18692687.001]
  • [Cites] Exp Hematol. 2008 Dec;36(12):1660-72 [18838202.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):665-74 [19693095.001]
  • [Cites] Physiology (Bethesda). 2005 Oct;20:349-56 [16174874.001]
  • (PMID = 20642818.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2914706
  •  go-up   go-down


73. Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, Franklin IM, Tallman MS, Cook L, Buck G, Durrant IJ, Rowe JM, Goldstone AH, Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood; 2006 Jul 15;108(2):465-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
  • Outcome of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) disease at diagnosis is unclear.
  • We treated 1508 de novo ALL patients with 2-phase induction and then high-dose methotrexate with l-asparaginase.
  • Patients up to 50 years old in first remission (CR1) with a matched related donor (MRD) underwent an allogeneic stem cell transplantation (SCT); the remainder in CR1 were randomized to an autologous SCT or intensive consolidation followed by maintenance chemotherapy.
  • Seventy-seven of 1508 (5%) patients a median age of 29 years had CNS leukemia at presentation; 13 of the 77 (17%) had Ph-positive ALL.
  • Seven of 27 treated with consolidation/maintenance remain in CR1 56 to 137 months after diagnosis.
  • Overall survival at 5 years was 29% in those with CNS involvement at diagnosis versus 38% (P = .03) for those without.
  • CNS leukemia in adult ALL is uncommon at diagnosis.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Br J Haematol. 1994 Sep;88(1):94-100 [7803263.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):70-82 [9045306.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2017-25 [10811665.001]
  • [Cites] Leukemia. 2001 Feb;15(2):208-16 [11236936.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):40-6 [14695849.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Med Pediatr Oncol. 1986;14(3):191-4 [3528788.001]
  • [Cites] Blood. 1987 Apr;69(4):1015-20 [3548841.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1014-30 [3163722.001]
  • [Cites] Blood. 1989 Jan;73(1):57-63 [2642717.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:175-7 [1578926.001]
  • [Cites] Leukemia. 1992 Nov;6 Suppl 4:49-51 [1434832.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):314-9 [8321259.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1990-2001 [8410124.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2091-7 [7662956.001]
  • (PMID = 16556888.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA14548; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1895498
  •  go-up   go-down


74. Lévy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, Legrand O, Sentenac S, Rousselot P, Raffoux E, Chast F, Chevret S, Marie JP: A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer; 2006 Aug 7;95(3):253-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.
  • To determine the maximum-tolerated dose (MTD), dose-limiting toxicities and pharmacokinetic of semisynthetic homoharringtonine (ssHHT), given as a twice daily subcutaneous (s.c.) injections for 9 days, in patients with advanced acute leukaemia, 18 patients with advanced acute myeloid leukaemia were included in this sequential Bayesian phase I dose-finding trial.
  • Eleven of the 12 patients with circulating leukaemic cells had blood blast clearance, two achieved complete remission and one with blast crisis of CMML returned in chronic phase.
  • [MeSH-major] Harringtonines / administration & dosage. Harringtonines / pharmacokinetics. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Injections, Subcutaneous. Male. Maximum Tolerated Dose. Middle Aged. Remission Induction. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Clin Oncol. 1989 Feb;25(2):263-9 [2702981.001]
  • [Cites] Clin Trials. 2006;3(1):57-71 [16539090.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 1989;37(1-2):69-76 [2619511.001]
  • [Cites] Cancer Res. 1990 Apr 1;50(7):2031-5 [2317793.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Biometrics. 1990 Mar;46(1):33-48 [2350571.001]
  • [Cites] Leukemia. 1992 Nov;6(11):1185-8 [1434802.001]
  • [Cites] Leukemia. 1992 Nov;6(11):1189-91 [1434803.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1695-700 [8400226.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):139-51 [11355928.001]
  • [Cites] Leukemia. 2001 Apr;15(4):567-74 [11368358.001]
  • [Cites] Stat Med. 2001 Oct 15;20(19):2827-43 [11568943.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1591-605 [11745238.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):888-93 [12942553.001]
  • [Cites] Comput Methods Programs Biomed. 2003 Oct;72(2):117-25 [12941516.001]
  • [Cites] J Zhejiang Univ Sci. 2004 Feb;5(2):230-4 [14674038.001]
  • [Cites] Mol Pharmacol. 1975 Sep;11(5):511-9 [1237080.001]
  • [Cites] Eur J Biochem. 1977 Jan;72(2):323-30 [319998.001]
  • [Cites] Cancer Treat Rep. 1983 Jul-Aug;67(7-8):693-6 [6871884.001]
  • [Cites] Cancer Treat Rep. 1983 Sep;67(9):801-4 [6883357.001]
  • [Cites] J Natl Cancer Inst. 1983 Oct;71(4):841-7 [6413744.001]
  • [Cites] Cancer Treat Rep. 1984 Sep;68(9):1085-91 [6478448.001]
  • [Cites] Cancer Chemother Pharmacol. 1985;14(3):206-10 [3995683.001]
  • [Cites] J Clin Oncol. 1985 May;3(5):617-21 [3889229.001]
  • [Cites] Invest New Drugs. 1985;3(3):279-86 [4066221.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):967-9 [3940656.001]
  • [Cites] Cancer Treat Rep. 1986 Dec;70(12):1403-7 [3791253.001]
  • [Cites] J Natl Cancer Inst. 1988 Sep 21;80(14):1095-103 [3045335.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):813-7 [2914287.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;23(3):145-50 [2924372.001]
  • [Cites] Bull Cancer. 1995 Dec;82(12):987-95 [8745664.001]
  • [Cites] Leukemia. 1997 May;11(5):624-8 [9180282.001]
  • [Cites] Cancer. 1997 Dec 1;80(11 Suppl):2205-9 [9395035.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 2):2723-33 [10068280.001]
  • [Cites] Cancer. 2005 May 1;103(9):1850-5 [15786422.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):609-13 [16434987.001]
  • [Cites] FEBS Lett. 1989 Nov 6;257(2):254-6 [2583270.001]
  • (PMID = 16847470.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Harringtonines; 6FG8041S5B / homoharringtonine
  • [Other-IDs] NLM/ PMC2360653
  •  go-up   go-down


75. Rodríguez Pérez A, López Carrizosa MC, Villalón Blanco L, Samper Ots PM, Ortiz Cruz E: Granulocytic sarcoma of the right humerus in a non-leukaemia patient. Clin Transl Oncol; 2008 Nov;10(11):758-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the right humerus in a non-leukaemia patient.
  • Granulocytic sarcoma (GS), an uncommon solid extramedullary tumour, should be considered even in the absence of leukaemia, as delay in diagnosis and treatment worsens the prognosis.
  • We present a GS (single humeral bone lesion) in a non-leukaemia patient, treated with intensive AML (Acute Myeloid Leukaemia) chemotherapy and sequential radiotherapy, in complete response 26 months after diagnosis, confirmed by histopathology and without leukaemia progression.
  • [MeSH-major] Bone Neoplasms / diagnosis. Humerus / pathology. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Arthroplasty, Replacement. Combined Modality Therapy. Cytarabine / administration & dosage. Female. Fractures, Spontaneous / etiology. Fractures, Spontaneous / surgery. Humans. Idarubicin / administration & dosage. Osteolysis / etiology. Remission Induction. Shoulder Fractures / etiology. Shoulder Fractures / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Med Clin (Barc). 1995 Mar 18;104(10):377-80 [7707732.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1100-3 [12764375.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2527-41 [17169797.001]
  • [Cites] Strahlenther Onkol. 2003 Mar;179(3):187-90 [12627262.001]
  • [Cites] Leuk Res. 2004 Nov;28(11):1165-9 [15380340.001]
  • [Cites] Orthopedics. 1999 Aug;22(8):773-5 [10465491.001]
  • (PMID = 19015073.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


76. Gerr H, Zimmermann M, Schrappe M, Dworzak M, Ludwig WD, Bradtke J, Moericke A, Schabath R, Creutzig U, Reinhardt D: Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol; 2010 Apr;149(1):84-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations.
  • Acute leukaemias of ambiguous lineage (ALAL) represent a rare type of leukaemia, expressing both myeloid and lymphoid markers.
  • This study retrospectively analyzed data from 92 children (biphenotypic n = 78, bilineal n = 6, lineage switch n = 8) with ALAL registered in the Berlin-Frankfürt-Münster (BFM) acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) studies between 1998 and 2006 (2.4% of all cases with acute leukaemia).
  • Our cohort of ALAL patients was characterized by comparatively high median age (8.9 years), high median white blood cell count (14.9 x 10(9)/l), as well as frequent hyperleucocytosis (18.5%) and central nervous system involvement (24.1%).
  • Complete remission rate was significantly lower than in ALL-BFM patients (91.8% vs. 99.1%, P < 0.001), but comparable to AML-BFM patients (87.9%).
  • Our data suggest that an intensive therapy regimen including stem cell transplantation may be favourable for bilineal or lineage switch cases, whereas patients with ETV6/RUNX1 fusion, lymphoid morphology and patients with expression of cyCD22 and cyCD79a should be treated with an ALL-directed therapy.
  • [MeSH-major] Leukemia / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Chromosome Aberrations. Hematopoietic Stem Cell Transplantation. Humans. Immunophenotyping. Infant. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20085575.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


77. Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS, Eastern Cooperative Oncology Group Leukemia Committee: Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol; 2010 Jan;148(2):217-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
  • The treatment of relapsed acute myeloid leukaemia (AML) remains unsatisfactory.
  • Eligible patients had primary refractory AML, a first relapse after a remission of <1 year, or a second or greater relapse.
  • The primary objective of this trial was attainment of a conventional complete remission (CR) or a CR without platelet recovery (CRp) in at least 40% of patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Immunosuppressive Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / administration & dosage. Daunorubicin / therapeutic use. Drug Therapy, Combination. Female. Humans. Liposomes. Male. Middle Aged. Recurrence. Remission Induction. Survival Analysis. Topotecan / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Leuk Lymphoma. 2005 Jun;46(6):795-802 [16019523.001]
  • [Cites] Am J Ther. 2006 Sep-Oct;13(5):389-93 [16988532.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):165-73 [16939487.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Exp Hematol. 2009 Jun;37(6):649-58 [19463767.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2819-30 [10561358.001]
  • [Cites] Invest New Drugs. 1999;17(1):81-7 [10555126.001]
  • [Cites] Leuk Res. 2009 Sep;33(9):1189-93 [19428106.001]
  • [Cites] Haematologica. 2000 Mar;85(3):324-5 [10702828.001]
  • [Cites] Leuk Lymphoma. 2000 Feb;36(5-6):479-84 [10784392.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):7-14 [11443603.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):308-15 [11841431.001]
  • [Cites] Klin Padiatr. 2002 Jul-Aug;214(4):188-94 [12165900.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1234-41 [12599230.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):915-20 [12792745.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):161-3 [12823360.001]
  • [Cites] Leuk Res. 2003 Oct;27(10):887-91 [12860007.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1544-50 [12886241.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4277-83 [12933575.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood Rev. 2004 Mar;18(1):39-63 [14684148.001]
  • [Cites] Leuk Res. 1984;8(4):521-34 [6590930.001]
  • [Cites] Blood. 1986 Apr;67(4):1048-53 [2937468.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1146-51 [8382970.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2824-5 [7522645.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2193-203 [7931489.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):44-51 [8996123.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40 Suppl:S9-12 [9272127.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-11-S20-26 [9425957.001]
  • [Cites] Br J Haematol. 1998 Feb;100(2):265-72 [9488612.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Leukemia. 1998 Sep;12 Suppl 1:S13-5 [9777888.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):210-20 [15813849.001]
  • [Cites] Drugs. 2005;65(16):2405-27 [16266206.001]
  • (PMID = 19804455.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00005962
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009337; United States / NCI NIH HHS / CA / CA14958; United States / NCI NIH HHS / CA / CA14548; United States / NCI NIH HHS / CA / U10 CA013650; United States / NCI NIH HHS / CA / U10 CA014958; United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA049883; United States / NCI NIH HHS / CA / CA13650; United States / NCI NIH HHS / CA / U10 CA017145; United States / NCI NIH HHS / CA / U10 CA021115-31; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / U10 CA066636; United States / NCI NIH HHS / CA / CA17145; United States / NCI NIH HHS / CA / U10 CA016116; United States / NCI NIH HHS / CA / U10 CA014548; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / CA49883; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA16116
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Liposomes; 04079A1RDZ / Cytarabine; 7M7YKX2N15 / Topotecan; 8N3DW7272P / Cyclophosphamide; 93NS566KF7 / gemtuzumab; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS152429; NLM/ PMC2809127
  •  go-up   go-down


78. Rapanotti MC, Caruso R, Ammatuna E, Zaza S, Trotta L, Divona M, Cicconi L, Funaro D, Federici G, Amadori S, De Rossi G, Lo-Coco F: Molecular characterization of paediatric idiopathic hypereosinophilia. Br J Haematol; 2010 Dec;151(5):440-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Molecular features of 10 pHES patients were analysed at presentation and during their clinical course, including analysis of BCR-ABL1 and FIP1L1/PDGFRA fusion genes, quantitation of WT1 gene copy number and clonality of T-cell receptor (TCR) and immunoglobulin heavy chain (IGH).
  • Five children showed IGH clonality at presentation: of these, two developed a B non-Hodgkin lymphoma and a B-lineage acute lymphocytic leukaemia at six and 12 months respectively, two spontaneously reverted to a polyclonal IGH profile during the follow-up, and the last one persisted with pHES without B-clonal evolution after 19 months.
  • One patient had a PDGFRA/FIP1L1 fusion and achieved hematologic and molecular remission after imatinib therapy.
  • IGH rearrangement was observed to be a frequent molecular feature of pHES and may precede B-cell clonal expansion and evolution into B-cell malignancies in children.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Follow-Up Studies. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. Infant. Lymphoma, B-Cell / etiology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20955401.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


79. Brummel B, Bernbeck B, Schneider DT: Complicated but successful treatment of a patient with ataxia telangiectasia and pre-B-acute lymphoblastic leukemia. Klin Padiatr; 2010 Nov;222(6):391-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complicated but successful treatment of a patient with ataxia telangiectasia and pre-B-acute lymphoblastic leukemia.
  • Pediatric patients may develop lymphomas and acute lymphoblastic leukaemia (ALL), especially of the T-lineage.
  • CASE REPORT: Here, we first report on a patient with AT and pre B-cell ALL.
  • Over 1 year after the end of the maintenance therapy the patient is still in complete first remission.
  • CONCLUSION: A general recommendation for dose modification in these patients group cannot be made due to the low number of patients suffering from AT and leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ataxia Telangiectasia / diagnosis. Ataxia Telangiectasia / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Child. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Remission Induction


80. Aydogdu I, Erkurt AM, Kaya E, Kuku I: Bone relapse in a patient with acute lymphoblastic leukaemia. Br J Haematol; 2005 Apr;129(2):163
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone relapse in a patient with acute lymphoblastic leukaemia.
  • [MeSH-major] Bone and Bones / pathology. Magnetic Resonance Imaging. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Femur / pathology. Fibula / pathology. Humans. Male. Patella / pathology. Recurrence. Remission Induction. Tibia / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813842.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


81. Yarranton H: Criteria for defining a complete remission in acute myeloid leukaemia. Br J Haematol; 2005 Apr;129(1):157-8; author reply 158
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for defining a complete remission in acute myeloid leukaemia.
  • [MeSH-major] Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Bone Marrow Cells / pathology. Humans. Remission Induction. Specimen Handling / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Haematol. 2005 Jan;128(2):184-91 [15638852.001]
  • (PMID = 15801968.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


82. Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR: Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol; 2010 Dec;151(5):430-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
  • Clofarabine and cytarabine target different steps in DNA synthesis and replication, are synergistic in vivo, and have non-overlapping toxicities, making this combination a potentially promising treatment for acute lymphocytic leukaemia.
  • Six out of 36 patients (17%) achieved a complete remission with or without complete count recovery; median overall survival was 3 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Apr 1;109(7):3080-3 [17170128.001]
  • [Cites] Br J Haematol. 2007 Mar;136(6):806-13 [17341266.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6 Suppl 5):S13-20 [18086342.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2563-72 [18156492.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):2927-35 [18483359.001]
  • [Cites] J Cell Physiol. 2000 Jan;182(1):119-26 [10567923.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):110-6 [11801546.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Development. 2003 Jun;130(12):2779-91 [12736220.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6335-42 [14695132.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] Development. 2004 May;131(9):2137-47 [15105373.001]
  • [Cites] Mol Pharmacol. 1988 Oct;34(4):485-91 [3050447.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2386-94 [1707752.001]
  • [Cites] Semin Hematol. 1991 Jul;28(3 Suppl 4):84-9 [1780759.001]
  • [Cites] Mol Biol Cell. 1993 Jun;4(6):637-45 [8374172.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2847-52 [7540950.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3030-7 [8674058.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1347-55 [9815818.001]
  • [Cites] Mol Pharmacol. 1999 Mar;55(3):515-20 [10051535.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3058-63 [15217837.001]
  • [Cites] Leukemia. 2005 Jan;19(1):64-8 [15510196.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55958-68 [15496414.001]
  • [Cites] Blood. 2005 Feb 1;105(3):940-7 [15486072.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):361-8 [15723262.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):8-20 [17910043.001]
  • (PMID = 21113977.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / CA073590; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA032102-32; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA76132; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA045450; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA073590; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / U10 CA058861
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 0 / CTGF protein, human; 0 / Neoplasm Proteins; 0 / Nucleoside Transport Proteins; 04079A1RDZ / Cytarabine; 139568-91-5 / Connective Tissue Growth Factor; 762RDY0Y2H / clofarabine
  • [Other-IDs] NLM/ NIHMS244575; NLM/ PMC3058291
  •  go-up   go-down


83. Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P: A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol; 2008 Sep;81(3):170-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both events occurred in patients with multiple myeloma and had similar characteristics, i.e. an acute episode of decrease in renal function (pre-existing nephropathy in one patient), with a metabolic profile and decrease in tumor burden consistent with tumor lysis syndrome.
  • However, five patients, including two patients with diffuse large-cell lymphoma [including one patient with transformed chronic myelocytic leukaemia (CLL)], two patients with CLL and one patient with multiple myeloma, achieved disease stabilization in of two to nine treatment cycles.
  • [MeSH-minor] Aged. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Histone Deacetylase Inhibitors. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Remission Induction. Sulfonamides. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510700.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Sulfonamides; F4H96P17NZ / belinostat
  •  go-up   go-down


84. Glynn RW, Miller N, Kerin MJ: 17q12-21 - the pursuit of targeted therapy in breast cancer. Cancer Treat Rev; 2010 May;36(3):224-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Finally, RARA may be the key to unlocking the problem of resistance to all-trans retinoic acid (ATRA) in breast cancer sufferers; this treatment has previously been demonstrated to induce remission in over 80% of patients with acute promyelocytic leukaemia (APML).
  • [MeSH-minor] Antigens, Neoplasm / physiology. Carrier Proteins / physiology. DNA Topoisomerases, Type II / physiology. DNA-Binding Proteins / physiology. Female. GRB7 Adaptor Protein / physiology. Humans. Membrane Proteins / physiology. Receptors, Retinoic Acid / physiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier Ltd.
  • (PMID = 20100636.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / GRB7 protein, human; 0 / Membrane Proteins; 0 / Receptors, Retinoic Acid; 0 / STARD3 protein, human; 0 / retinoic acid receptor alpha; 149058-53-7 / GRB7 Adaptor Protein; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Number-of-references] 58
  •  go-up   go-down


85. Amadori S, Fenaux P, Ludwig H, O'dwyer M, Sanz M: Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin; 2005 Mar;21(3):403-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Arsenic trioxide delivers high rates of complete clinical remission in patients with relapsed/refractory acute promyelocytic leukaemia (APL), and is associated with high rates of molecular remission as indicated by PCR negativity for the PML-RARalpha gene.
  • Investigations of this agent are ongoing in a range of haematological malignancies, and studies in newly diagnosed APL, acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), multiple myeloma (MM) and chronic myelogenous leukaemia (CML) are reviewed here using published articles and presentations at international congresses to June 2004.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15811209.001).
  • [ISSN] 0300-7995
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 75
  •  go-up   go-down


86. Nasir TA, Kabir A: Chemotherapy induced toxicities in therapeutic trials of Acute Lymphoblastic Leukaemia. Mymensingh Med J; 2005 Jan;14(1):61-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy induced toxicities in therapeutic trials of Acute Lymphoblastic Leukaemia.
  • It is common practice in therapeutic trials in Acute Lymphoblastic Leukaemia (ALL) to treat chemotherapy induced toxicities.
  • Remission induction, consolidation and maintenance therapy with conventional combination chemotherapy and CNS prophylaxis with intrathecal methotrexate and radiotherapy were instituted to all patients for long term event free survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695958.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


87. Proctor SJ, Chapman CE, Sharples R, Lucraft HL, Wilkinson J, Conn J, Middleton PG: Enhanced engraftment of a very low-dose cord blood unit in an adult haemopoietic transplant by addition of six mismatched viable cord units. Stem Cells Int; 2010;2010:431909
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The report describes the feasibility of the addition of multiple viable HLA-mismatched unrelated cord blood units, to a low cell number matched unrelated cord, to assist clinical engraftment.
  • An ablative stem cell transplant was performed in an adult with relapsed acute lymphoblastic leukaemia (ALL), using a single HLA-matched cord blood unit (mononuclear cell dose 0.8 × 10(7)), supported by six mismatched cord blood units (one unit per 10 kg recipient weight).
  • Early molecular remission of ALL was demonstrated using a novel PCR for a mitochondrial DNA mutation in the leukaemic clone.
  • The cell dose of the matched cord was well below that recommended to engraft a 70 kg recipient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048848.001).
  • [ISSN] 1687-9678
  • [Journal-full-title] Stem cells international
  • [ISO-abbreviation] Stem Cells Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2956468
  •  go-up   go-down


88. Sikorska-Fic B, Stańczak E, Matysiak M, Kamiński A: [Acute pancreatitis during chemotherapy of acute lymphoblastic leukaemia complicated with pseudocyst]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1051-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute pancreatitis during chemotherapy of acute lymphoblastic leukaemia complicated with pseudocyst].
  • Acute haemorrhagic or necrotizing pancreatitis caused by L-asparaginase is rare but potentially life-threatening complication.
  • We present 2 cases of acute pancreatitis in children aged 2 and 4 years.
  • They were diagnosed to have acute lymphoblastic leukaemia and were treated according to the ALLLIC BFM 2002 protocol.
  • Acute pancreatitis developed in these children after induction therapy and was followed by formation of a pseudocyst.
  • In both cases the diagnosis of this complication was made directly after phase I of the protocol I (after eighth dose of L-Asparaginase).
  • In the first case the course of acute pancreatitis was mild.
  • Normalization of the amylase levels occurred after 7 days and the diagnosis of post inflammatory cyst was made 15 days after the first signs of the disease.
  • In the second case acute pancreatitis had a severe course and the child required treatment in the Intensive Care Unit for 21 days.
  • Currently both children are well and remain in haematological remission and continue maintenance chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Pancreatic Pseudocyst / complications. Pancreatitis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Asparaginase / administration & dosage. Asparaginase / adverse effects. Asparaginase / therapeutic use. Child, Preschool. Daunorubicin / adverse effects. Daunorubicin / therapeutic use. Drainage. Female. Humans. Prednisone / adverse effects. Prednisone / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531825.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


89. Braham Jmili N, Omri H, Senana Sendi H, Fekih S, Hizem S, Sriha B, Khelif A, Saad A, Kortas M: Identification of the translocation t(15;17) in acute myeloid leukemia (AML) initially classified as FAB M1: case report and review of the literature. Clin Lab; 2006;52(3-4):125-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the translocation t(15;17) in acute myeloid leukemia (AML) initially classified as FAB M1: case report and review of the literature.
  • The diagnosis of acute myeloid leukaemia (AML) was then evoked initially.
  • One month later, he was discharged from hospital on hematological and cytogenetic remission.
  • From the biological findings the patient was retrospectively diagnosed as having promyelocytic leukemia (hyperbasophilic form).
  • [MeSH-major] Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Leukemia, Myeloid, Acute / genetics. Leukemia, Promyelocytic, Acute / genetics. Neoplasms, Second Primary / genetics. Translocation, Genetic


90. Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, Edan G: Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry; 2008 Jan;79(1):52-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient was diagnosed with acute myeloid leukaemia (remission 5 years after diagnosis).

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846110.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Immunosuppressive Agents; 0 / Peptides; 5M691HL4BO / Glatiramer Acetate; 77238-31-4 / Interferon-beta; BZ114NVM5P / Mitoxantrone; MRK240IY2L / Azathioprine; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


91. Bruserud Ø, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT: Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets; 2006 Feb;10(1):51-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several new therapeutic strategies are now considered for acute myelogenous leukaemia (AML), including modulation of protein lysine acetylation through inhibition of histone deacetylases (HDACs): a large group of enzymes that alters the acetylation and, thereby, the function of a wide range of nuclear and cytoplasmic proteins.
  • Secondly, acetylation is an important post-translational modulation of several proteins involved in the regulation of cell proliferation, differentiation and apoptosis (e.g., p53, tubulin, heat-shock protein 90).
  • Complete haematological remission lasting for several months has been reported for a few patients (< 5% of included patients), whereas increased peripheral blood platelet counts seem more common and have been described both for patients with AML and myelodysplastic syndromes.
  • [MeSH-major] Drug Delivery Systems / methods. Hematopoiesis / drug effects. Histone Deacetylases / metabolism. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / enzymology. Lysine / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Lysine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441228.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; EC 3.5.1.98 / Histone Deacetylases; K3Z4F929H6 / Lysine
  • [Number-of-references] 136
  •  go-up   go-down


92. Craddock C, Tauro S, Moss P, Grimwade D: Biology and management of relapsed acute myeloid leukaemia. Br J Haematol; 2005 Apr;129(1):18-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology and management of relapsed acute myeloid leukaemia.
  • Disease relapse remains the major cause of treatment failure in adults with acute myeloid leukaemia (AML).
  • This reflects both the failure of current salvage regimens and the absence of effective strategies to secure long-term disease-free survival in those patients who achieve a second remission.
  • At the same time, advances in allogeneic stem-cell transplantation have permitted the extension of the curative potential of allografting to patients in whom it was previously contraindicated.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / contraindications. Humans. Immunologic Factors / therapeutic use. Recurrence. Salvage Therapy / methods. Stem Cell Transplantation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15801952.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors
  • [Number-of-references] 156
  •  go-up   go-down


93. Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH: Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother; 2008 Mar;61(3):734-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients.
  • OBJECTIVES: Presumed or proven invasive pulmonary aspergillosis (IPA) is an important cause of infectious morbidity in patients with acute leukaemia.
  • Although prior IPA is not a contraindication for subsequent allogeneic haematopoietic stem cell transplantation (HSCT), its management during granulocytopenia and immunosuppression remains challenging.
  • PATIENTS AND METHODS: In the absence of an evidence-based approach, 11 adolescents (11-18 years) with acute leukaemia and a history of antecedent possible (4) or probable (7) IPA received liposomal amphotericin B (LAMB; 1 mg/kg once a day) from the start of the conditioning regimen until engraftment and ability to take oral medication, followed by oral voriconazole (200 mg twice a day) until the end of the at-risk period.
  • At +180 days post-transplant, eight patients were alive, six with complete, and one each with near complete and ongoing resolution of pulmonary infiltrates; all but one were in continuing haematological remission.
  • Three patients had succumbed either to recurrent leukaemia (two) or refractory graft failure (one); whereas one of these patients had maintained a complete response, two died with secondary possible (one) or probable (one) IPA.
  • In the absence of chronic graft-versus-host disease, breakthrough infection appeared to be associated with recurrent leukaemia/graft failure and shorter duration of post-engraftment prophylaxis.
  • [MeSH-major] Antifungal Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Hematopoietic Stem Cells / drug effects

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18238891.001).
  • [ISSN] 1460-2091
  • [Journal-full-title] The Journal of antimicrobial chemotherapy
  • [ISO-abbreviation] J. Antimicrob. Chemother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


94. Ferrara F, Fazi P, Venditti A, Pagano L, Amadori S, Mandelli F: Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party. Hematol Oncol; 2008 Jun;26(2):104-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party.
  • The percentage of long-term survivors in acute myeloid leukaemia (AML) in the elderly does not exceed 10-15% of patients enrolled into clinical trials because of lower complete remission (CR) rates and higher incidence of relapse.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Age Factors. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Italy. Male. Medical Oncology / methods. Middle Aged. Recurrence. Remission Induction. Salvage Therapy. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271064.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


95. Maha A, Cheong SK, Leong CF, Seow HF: Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy. Malays J Pathol; 2009 Dec;31(2):81-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy.
  • It is postulated that in cells of chemo-sensitive patients, chemotherapy induces apoptotic signals leading to cell death while survival signals are maintained in cells of chemo-resistant patients.
  • We examined the expression pattern of proinflammatory cytokines, signaling molecules of the PI3K and MAPK pathways molecules and death receptor, DR5 on paired samples at diagnosis and during chemotherapy in acute myeloid leukaemia patients treated with cytosine arabinoside and daunorubicin.
  • The results were correlated with remission status one month after chemotherapy.
  • Thus, expression of TNF-alpha, IL-6, DR5, phospho-p38 and phospho-Jnk may regulate cell death in chemo-sensitive cases.
  • IL-beta and IL-18 were also found to be higher in chemo-resistant cases at diagnosis and during chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Drug Resistance, Neoplasm / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Leukemia, Myeloid, Acute / drug therapy. Signal Transduction / drug effects
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cytarabine / administration & dosage. Cytokines / drug effects. Cytokines / genetics. Cytokines / metabolism. Daunorubicin / administration & dosage. Elafin / drug effects. Elafin / genetics. Elafin / metabolism. Female. Humans. Male. Middle Aged. Mitogen-Activated Protein Kinases / drug effects. Mitogen-Activated Protein Kinases / genetics. Mitogen-Activated Protein Kinases / metabolism. Prognosis. RNA, Messenger / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand / drug effects. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism. Remission Induction. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514850.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Elafin; 0 / PI3 protein, human; 0 / RNA, Messenger; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 04079A1RDZ / Cytarabine; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


96. Zaliova M, Fronkova E, Krejcikova K, Muzikova K, Mejstrikova E, Stary J, Trka J, Zuna J: Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring. Leukemia; 2009 May;23(5):944-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minimal residual disease (MRD) monitoring is an essential tool for risk group stratification in current treatment protocols for childhood acute lymphoblastic leukaemia (ALL).
  • Although quantitative detection of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements is currently considered to be the standard method, leukaemia fusion genes provide other possible targets for MRD follow-up, as already demonstrated in TEL/AML1-positive ALLs.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Neoplasm Recurrence, Local / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Cells, Cultured. Child. Child, Preschool. Female. Gene Rearrangement, T-Lymphocyte / genetics. Genes, Immunoglobulin / genetics. Humans. Male. Neoplasm, Residual / genetics. Precursor Cells, B-Lymphoid / metabolism. Precursor Cells, B-Lymphoid / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Remission Induction. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19158828.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


97. Gonen C, Haznedaroglu IC, Aksu S, Koca E, Göker H, Büyükaşik Y, Sayinalp N, Ozcebe O, Dündar S: Endogenous thrombopoietin levels during the clinical management of acute myeloid leukaemia. Platelets; 2005 Feb;16(1):31-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous thrombopoietin levels during the clinical management of acute myeloid leukaemia.
  • Thrombocytopenia represents a major problem in the management of acute myeloid leukaemia (AML).
  • We serially measured both TPO and platelets concurrently over the entire treatment period of newly diagnosed patients receiving both remission induction and consolidation chemotherapies.
  • The median concentration of TPO in AML patients at the initial diagnosis was 469.71 pg/ml and increased significantly during the aplastic period due to remission induction chemotherapy (median: 1085.33 pg/ml) but then decreased to a level (median: 45.26 pg/ml) encountered in the healthy control subjects (median: 56.90 pg/ml).
  • [MeSH-major] Leukemia, Myeloid / blood. Thrombopoietin / blood
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Agents / therapeutic use. Blood Platelets / drug effects. Case-Control Studies. Disease Management. Female. Humans. Infection / blood. Infection / etiology. Male. Middle Aged. Platelet Count. Remission Induction. Thrombocytopenia / blood. Thrombocytopenia / etiology. Thrombopoiesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763894.001).
  • [ISSN] 0953-7104
  • [Journal-full-title] Platelets
  • [ISO-abbreviation] Platelets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9014-42-0 / Thrombopoietin
  •  go-up   go-down


98. Lu X, Kondo Y, Takamatsu H, Ohata K, Yamazaki H, Takami A, Akatsuka Y, Nakao S: CD16+ CD56- NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus-leukemia effect. Eur J Haematol; 2008 Jul;81(1):18-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD16+ CD56- NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus-leukemia effect.
  • A marked increase in CD16+ CD56- NK cells in the peripheral blood (PB) was observed in a cord blood transplant (CBT) recipient with refractory acute myeloid leukaemia (AML) in association with attaining molecular remission.
  • Although cultured CD16+CD56- NK cells retained the killer-cell immunoglobulin receptor (KIR)-ligand (KIR-L) specificity and the patient's leukemic cells expressed corresponding KIR ligands, they killed patient's leukemic cells expressing ULBP2.
  • An increase in the CD16+CD56- NK cell count (0.5 x 10(9)/L or more) in PB was observed in seven of 11 (64%) CBT recipients but in none of 13 bone marrow (BM) and eight peripheral blood stem cell (PBSC) transplant recipients examined during the similar period after transplantation.
  • These findings suggest an increase in CD16+CD56- NK cells to be a phenomenon unique to CBT recipients and that mature NK cells derived from this NK cell subset may contribute to the killing of leukemic cells expressing NKG2D ligands in vivo.
  • [MeSH-major] Antigens, CD56. Cord Blood Stem Cell Transplantation. Killer Cells, Natural / cytology. Killer Cells, Natural / immunology. Receptors, IgG
  • [MeSH-minor] Blood Cells. Cells, Cultured. Cytotoxicity, Immunologic. GPI-Linked Proteins. Graft vs Leukemia Effect. Humans. Immunophenotyping. Intercellular Signaling Peptides and Proteins. Lymphocyte Count

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363874.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Receptors, IgG; 0 / ULBP2 protein, human
  •  go-up   go-down


99. Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK: Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol; 2010 Nov;151(4):295-311
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.
  • Modifications to the treatment of acute lymphoblastic leukaemia (ALL) in children have led to a dramatic increase in survival in the past 40 years.
  • Despite this success, a significant subset of paediatric leukaemia patients either relapse or fail to ever achieve a complete remission.
  • Many novel targeted therapies for the treatment of childhood ALL provide potential mechanisms to further improve cure rates, and provide the possibility of minimizing toxicity to non-malignant cells, given their specificity to malignant cell phenotypes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Molecular Targeted Therapy / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • [Cites] Pediatr Res. 2005 Mar;57(3):430-7 [15659698.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1545-50 [15746059.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1430-41 [15846298.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Aug;56(2):126-37 [15841378.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1049-58 [16038731.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1400-6 [15878982.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3532-7 [16051737.001]
  • [Cites] Cancer Immunol Immunother. 2006 May;55(5):503-14 [16032400.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2643-52 [16352804.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):13-23 [16292537.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2662-9 [16675557.001]
  • [Cites] J Cell Biol. 2006 Jun 19;173(6):833-7 [16769825.001]
  • [Cites] Mol Cancer Ther. 2009 Jul;8(7):1808-17 [19567821.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):505-8 [19418547.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):978-83 [19637330.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2678-87 [19643988.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1243-6 [19838194.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5175-81 [19805687.001]
  • [Cites] Cancer Cell. 2009 Nov 6;16(5):401-12 [19878872.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5459-68 [19826124.001]
  • [Cites] Blood. 2007 Jul 15;110(2):678-85 [17395781.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1269-82 [17613754.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1500-9 [17499001.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1043-50 [17640858.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2774-5 [17881645.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9490-500 [17909059.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2240-5 [17657218.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):37-45 [17420992.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1639-48 [18347165.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 Dec;31(12):936-41 [19875969.001]
  • [Cites] Pediatr Blood Cancer. 2010 Feb;54(2):307-10 [19856388.001]
  • [Cites] Blood. 2009 Dec 17;114(26):5271-8 [19843886.001]
  • [Cites] Blood. 2009 Dec 24;114(27):5490-8 [19855078.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7 [20018760.001]
  • [Cites] Nat Med. 2010 Feb;16(2):205-13 [20072130.001]
  • [Cites] Leukemia. 2010 Feb;24(2):355-70 [20016527.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1425-32 [20007803.001]
  • [Cites] Blood. 2010 Jul 1;115(26):5312-21 [20139093.001]
  • [Cites] Bioconjug Chem. 2009 Aug 19;20(8):1587-94 [19572629.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Feb 28;175(1):134-42 [1998499.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Leuk Res. 1992 Jun-Jul;16(6-7):597-605 [1635378.001]
  • [Cites] Blood. 1992 Dec 1;80(11):2826-34 [1280479.001]
  • [Cites] Clin Exp Immunol. 1992 Dec;90(3):368-75 [1281055.001]
  • [Cites] Blood. 1993 Feb 15;81(4):1025-31 [8427984.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24057-66 [11929866.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2255-7 [12369853.001]
  • [Cites] Genes Cells. 2002 Nov;7(11):1173-82 [12390251.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8173-7 [12444553.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1637-44 [12393484.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Ann Intern Med. 2003 May 20;138(10):819-30 [12755554.001]
  • [Cites] Blood. 2003 Jul 1;102(1):269-75 [12623837.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7638-43 [12794186.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1824-32 [12738674.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4483-93 [14555522.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] Leukemia. 2004 Mar;18(3):521-9 [14712291.001]
  • [Cites] Leukemia. 2004 Apr;18(4):676-84 [14961035.001]
  • [Cites] Blood. 2004 May 1;103(9):3544-6 [14670924.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4268-75 [14976048.001]
  • [Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Toxicol Sci. 2004 Nov;82(1):341-58 [15319485.001]
  • [Cites] Nature. 1984 Aug 16-22;310(5978):583-6 [6087162.001]
  • [Cites] Science. 1987 Jan 2;235(4784):85-8 [3541203.001]
  • [Cites] Nature. 1987 Feb 12-18;325(6105):631-5 [3543692.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):14701-4 [2203759.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18141-4 [10373409.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Adv Exp Med Biol. 1999;457:325-33 [10500808.001]
  • [Cites] Blood. 2005 Jan 15;105(2):812-20 [15374878.001]
  • [Cites] Nat Med. 2005 Jan;11(1):71-6 [15619634.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1680-3 [9733516.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1344-8 [9737681.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27084-90 [9765224.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):189-93 [9771714.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):680-5 [9892693.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):715-22 [10048973.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1181-9 [18085673.001]
  • [Cites] Blood. 2008 May 15;111(10):5093-100 [18349321.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):34-41 [18260120.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1101-9 [18483299.001]
  • [Cites] J Biol Chem. 2008 Jun 27;283(26):18292-302 [18434310.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):909-15 [8164041.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):292-301 [7575604.001]
  • [Cites] Cell. 1995 Oct 20;83(2):289-99 [7585946.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2870-7 [8639906.001]
  • [Cites] Nature. 1996 Feb 15;379(6566):645-8 [8628398.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] Oncogene. 1996 Dec 19;13(12):2589-94 [9000132.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):43-9 [9422522.001]
  • [Cites] Semin Immunol. 1998 Aug;10(4):287-97 [9695185.001]
  • [Cites] Leukemia. 2000 Mar;14(3):399-402 [10720133.001]
  • [Cites] Blood. 2000 Jul 15;96(2):676-84 [10887134.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):817-25 [10952788.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Biochemistry. 2001 Jan 30;40(4):1117-23 [11170436.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Cell Death Differ. 2001 Oct;8(10):1014-21 [11598799.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46639-46 [11583996.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3885-91 [12010785.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(4):685-99 [16997177.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6092-100 [16652142.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):31-40 [16865529.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):327-33 [17080335.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1783-8 [17363533.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1789-93 [17363534.001]
  • [Cites] Adv Cancer Res. 2008;100:35-83 [18620092.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Blood. 2008 Sep 1;112(5):2020-3 [18544682.001]
  • [Cites] Cancer. 2008 Sep 1;113(5):985-94 [18615627.001]
  • [Cites] Pathol Oncol Res. 2008 Sep;14(3):275-9 [18575824.001]
  • [Cites] Semin Oncol. 2008 Oct;35(5):484-93 [18929147.001]
  • [Cites] Oncologist. 2008 Nov;13(11):1181-92 [18987046.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):218-21 [18692895.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Leuk Lymphoma. 2009 Jun;50(6):886-91 [19455460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Leukemia. 2009 Jul;23(7):1342-3 [19322208.001]
  • (PMID = 20813012.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD000850; United States / NCI NIH HHS / CA / P50 CA058187; United States / NCI NIH HHS / CA / R01 CA137078; United States / NCI NIH HHS / CA / 5P50CA058187
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; EC 2.7.- / Phosphotransferases
  • [Other-IDs] NLM/ NIHMS374428; NLM/ PMC3354740
  •  go-up   go-down


100. Al-Shughair N, Al-Dawsari G, Gyger M, Mohamed G, Roberts G: Clinical significance of plasmacytosis in the day+14 bone marrow of patients with acute myeloid leukaemia undergoing induction chemotherapy. J Clin Pathol; 2007 May;60(5):520-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of plasmacytosis in the day+14 bone marrow of patients with acute myeloid leukaemia undergoing induction chemotherapy.
  • BACKGROUND: The design of chemotherapy-induction regimens for acute myeloid leukaemia (AML) is directed towards the early elimination of bone marrow (BM) leukaemic blast cells (LBCs).
  • METHODS: On the 14th day after the start of chemotherapy (D+14) BM samples were examined for residual PCs in 60 adult (>or=15 years) patients undergoing AML-induction chemotherapy, and the proportion of PCs was related to blood and BM parameters including French-American-British (FAB) subtype, other inflammatory cells, antecedent infection, attainment of complete remission and 36-month survival.
  • Higher numbers of residual PCs also reflected the presence of infection before diagnosis and coincident with treatment (p=0.039).
  • Although we could not demonstrate an association between PC numbers and 36-month survival, PC numbers were significantly higher in patients with residual leukaemia at D>14 (p=0.007).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Cells / pathology. Leukemia, Myeloid / drug therapy. Plasma Cells / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Female. Humans. Lymphocyte Count. Male. Middle Aged. Neoplasm, Residual. Opportunistic Infections / pathology. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Br J Cancer. 1977 Mar;35(3):265-72 [322689.001]
  • [Cites] Br J Haematol. 1977 Jan;35(1):61-9 [869995.001]
  • [Cites] Br J Cancer. 1978 Feb;37(2):282-8 [272913.001]
  • [Cites] Ann Hematol. 1998 Jun;76(6):273-7 [9692816.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2081-7 [2478222.001]
  • [Cites] Hematol Pathol. 1994;8(1-2):43-51 [8034557.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2672-80 [7919380.001]
  • [Cites] Leuk Lymphoma. 1996 Mar;21(1-2):49-52 [8907269.001]
  • [Cites] Nouv Rev Fr Hematol. 1986;28(5):281-5 [3808938.001]
  • (PMID = 16731597.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1994521
  •  go-up   go-down






Advertisement